BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-galluzzi C, Mckenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR. The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters. American Journal of Surgical Pathology 2013;37:1490-504. [DOI: 10.1097/pas.0b013e318299f0fb] [Cited by in Crossref: 471] [Cited by in F6Publishing: 509] [Article Influence: 47.1] [Reference Citation Analysis]
Number Citing Articles
1 Xu P, Zhang S, Cheng J, Cao B, Huang J, Li Y, Lin W, Li H, Chen W, Zhu Y, Jiang S, Hu X, Wu J, Wu Z, Zhou J, Guo J, Cheng J, Wang H. Prognostic value of tumour contour irregularity on surgical strategies for T1bN0M0 renal cell carcinoma: A multi-institutional study. Eur J Radiol 2023;159:110665. [PMID: 36566705 DOI: 10.1016/j.ejrad.2022.110665] [Reference Citation Analysis]
2 Nyman J, Denize T, Bakouny Z, Labaki C, Titchen BM, Bi K, Hari SN, Rosenthal J, Mehta N, Jiang B, Sharma B, Felt K, Umeton R, Braun DA, Rodig S, Chouieri TK, Signoretti S, Van Allen EM. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. bioRxiv 2023:2023. [PMID: 36712053 DOI: 10.1101/2023.01.18.524545] [Reference Citation Analysis]
3 Alaghehbandan R, Siadat F, Trpkov K. What's new in the WHO 2022 classification of kidney tumours? Pathologica 2023. [PMID: 36645398 DOI: 10.32074/1591-951X-818] [Reference Citation Analysis]
4 Martín-Saiz L, Abad-García B, Solano-Iturri JD, Mosteiro L, Martín-Allende J, Rueda Y, Pérez-Fernández A, Unda M, Coterón-Ochoa P, Goya A, Saiz A, Martínez J, Ochoa B, Fresnedo O, Larrinaga G, Fernández JA. Using the Synergy between HPLC-MS and MALDI-MS Imaging to Explore the Lipidomics of Clear Cell Renal Cell Carcinoma. Anal Chem 2023;95:2285-93. [PMID: 36638042 DOI: 10.1021/acs.analchem.2c03953] [Reference Citation Analysis]
5 John A, Spain L, Hamid AA. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature. Curr Oncol 2023;30:923-37. [PMID: 36661719 DOI: 10.3390/curroncol30010070] [Reference Citation Analysis]
6 Huang X, Nie F, Zhu J, Liu L, Wang N. Diagnostic Value of Contrast-Enhanced Ultrasound Features for WHO/ISUP Grading in Renal Cell Carcinoma. J Ultrasound Med 2023. [PMID: 36591798 DOI: 10.1002/jum.16171] [Reference Citation Analysis]
7 Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. J Immunother Cancer 2022;10. [PMID: 36549781 DOI: 10.1136/jitc-2022-005445] [Reference Citation Analysis]
8 Cimadamore A, Caliò A, Marandino L, Marletta S, Franzese C, Schips L, Amparore D, Bertolo R, Muselaers S, Erdem S, Ingels A, Pavan N, Pecoraro A, Kara Ö, Roussel E, Carbonara U, Campi R, Marchioni M; EAU-YAU Renal Cancer Working Group. Hot topics in renal cancer pathology: implications for clinical management. Expert Rev Anticancer Ther 2022;22:1275-87. [PMID: 36377655 DOI: 10.1080/14737140.2022.2145952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Grewal R, Choung HYG, Roberts LL, Beane T, Chen L, Gilroy DX, Rappold PM, Le TH. TMEM27 expression and clinical characteristics and survival in clear cell renal cell carcinoma. Acta Oncol 2022;61:1507-11. [PMID: 36369873 DOI: 10.1080/0284186X.2022.2143279] [Reference Citation Analysis]
10 Akgul M, Williamson SR. How New Developments Impact Diagnosis in Existing Renal Neoplasms. Surgical Pathology Clinics 2022;15:695-711. [DOI: 10.1016/j.path.2022.07.005] [Reference Citation Analysis]
11 Zhang X, Zhang G, Xu L, Bai X, Zhang J, Chen L, Lu X, Yu S, Jin Z, Sun H. Prediction of World Health Organization /International Society of Urological Pathology (WHO/ISUP) Pathological Grading of Clear Cell Renal Cell Carcinoma by Dual-Layer Spectral CT. Academic Radiology 2022. [DOI: 10.1016/j.acra.2022.12.002] [Reference Citation Analysis]
12 Chen S, Zhao Y, Tang Q, Wu C, Wang A, Ma L, Zhang X, Chen J, Gao Y, Liao X, Feng N, Fan Y, Zhang J, Li X, Liu M. Diagnostic performance and prognostic value of preoperative 18F-FDG PET/CT in renal cell carcinoma patients with venous tumor thrombus. Cancer Imaging 2022;22:65. [DOI: 10.1186/s40644-022-00502-1] [Reference Citation Analysis]
13 Liu XH, Zou QM, Cao JD, Wang ZC. Primary squamous cell carcinoma with sarcomatoid differentiation of the kidney associated with ureteral stone obstruction: A case report . World J Clin Cases 2022; 10(32): 11942-11948 [DOI: 10.12998/wjcc.v10.i32.11942] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Li S, Zhu J, He Z, Ashok R, Xue N, Liu Z, Ding L, Zhu H. Development and validation of nomograms predicting postoperative survival in patients with chromophobe renal cell carcinoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.982833] [Reference Citation Analysis]
15 Wang T, Ding X, Huang X, Ye J, Li H, Cao S, Gao Y, Ma X, Huang Q, Wang B. Papillary renal neoplasm with reverse polarity-a comparative study with CCPRCC, OPRCC, and PRCC1. Hum Pathol 2022;129:60-70. [PMID: 35977593 DOI: 10.1016/j.humpath.2022.07.010] [Reference Citation Analysis]
16 Di Maida F, Campi R, Grosso AA, Lambertini L, Cadenar A, Giudici S, Pecoraro A, Mari A, Serni S, Minervini A, Belmonte M, Catucci C, Mariottini R, Marzocco A, Moscardi L, Livio V, Mazzola L. Prognostic features of upstaged pT3a renal tumors with fat invasion after robot-assisted partial nephrectomy: is it time for a new subclassification? European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.11.098] [Reference Citation Analysis]
17 Grosso AA, Di Maida F, Tellini R, Viola L, Lambertini L, Valastro F, Mari A, Masieri L, Carini M, Minervini A. Assessing the impact of socio-economic determinants on access to care, surgical treatment options and outcomes among patients with renal mass: Insight from the universal healthcare system. Eur J Cancer Care (Engl) 2022;31:e13666. [PMID: 35869594 DOI: 10.1111/ecc.13666] [Reference Citation Analysis]
18 Bigot P, Barthelemy P, Boissier R, Khene Z, Pettenati C, Bernhard J, Correas J, Doumerc N, Gimel P, Ingels A, Nouhaud F, Ouzaïd I, Rioux-leclercq N, Albiges L, Rouprêt M. French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. Progrès en Urologie 2022;32:1195-1274. [DOI: 10.1016/j.purol.2022.07.146] [Reference Citation Analysis]
19 Li J, Li X, Jiang Z, Hu C, Liu J, Huo J, Liu B. Predicting the probability of malignant pathological type of kidney cancer based on mass size: A retrospective study. Prog Urol 2022;32:849-55. [PMID: 36068150 DOI: 10.1016/j.purol.2022.08.007] [Reference Citation Analysis]
20 Salmond JM. Pathology of tumours of the kidney and urinary tract. Surgery (Oxford) 2022;40:627-632. [DOI: 10.1016/j.mpsur.2022.08.002] [Reference Citation Analysis]
21 Midenberg E, Higgins MI, Schmeusser BN, Patil DH, Zaldumbide J, Martini DJ, Steele S, Williams M, Nabavizadeh R, Psutka SP, Ogan K, Bilen MA, Master VA. Prognostic Value of Sarcopenia and Albumin in the Surgical Management of Localized Renal Cell Carcinoma. Urologic Oncology: Seminars and Original Investigations 2022. [DOI: 10.1016/j.urolonc.2022.09.020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Kolar J, Llaurado AF, Ulamec M, Skenderi F, Perez-montiel D, Alvarado-cabrero I, Bulimbasic S, Sperga M, Tretiakova M, Osunkoya AO, Rogala J, Comperat E, Gal V, Dunatov A, Pivovarcikova K, Michalova K, Vesela AB, Slisarenko M, Strakova AP, Pitra T, Hora M, Michal M, Alaghehbandan R, Hes O. Histologic diversity in chromophobe renal cell carcinoma does not impact survival outcome: A comparative international multi-institutional study. Annals of Diagnostic Pathology 2022;60:151978. [DOI: 10.1016/j.anndiagpath.2022.151978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zanjani LS, Vafaei S, Abolhasani M, Fattahi F, Madjd Z. Prognostic value of Talin-1 in renal cell carcinoma and its association with B7-H3. CBM 2022. [DOI: 10.3233/cbm-220018] [Reference Citation Analysis]
24 Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. [PMID: 36174377 DOI: 10.1016/j.ctarc.2022.100640] [Reference Citation Analysis]
25 Demirel E, Dilek O. A new finding for the obesity paradox? Evaluation of the relationship between muscle and adipose tissue in nuclear grade prediction in patients with clear cell renal cell carcinoma. Acta Radiol. [DOI: 10.1177/02841851221126358] [Reference Citation Analysis]
26 Alnazer I, Falou O, Bourdon P, Urruty T, Guillevin R, Khalil M, Shahin A, Fernandez-maloigne C. Usefulness of computed tomography textural analysis in renal cell carcinoma nuclear grading. J Med Imag 2022;9. [DOI: 10.1117/1.jmi.9.5.054501] [Reference Citation Analysis]
27 Zuo Y, Fu S, Zhao Z, Li Z, Wu Y, Qi T, Zheng J, Du Q, Xu Z, Yu N. Sarcomatoid-associated gene risk index for clear cell renal cell carcinoma. Front Genet 2022;13:985641. [DOI: 10.3389/fgene.2022.985641] [Reference Citation Analysis]
28 Chrabańska M, Rynkiewicz M, Kiczmer P, Drozdzowska B. Immunohistochemical Expression of CD44, MMP-2, MMP-9, and Ki-67 as the Prognostic Markers in Non-Clear Cell Renal Cell Carcinomas-A Prospective Cohort Study. J Clin Med 2022;11:5196. [PMID: 36079127 DOI: 10.3390/jcm11175196] [Reference Citation Analysis]
29 Jiang H, Zhou X, Zhan X, Li Y, Xiong Y, Long J, Li S, Liu X, Fu B. Clinical study of centrality index in predicting the postoperative pathological nuclear grade of clear cell renal cell carcinoma. Int Urol Nephrol 2022. [PMID: 36030357 DOI: 10.1007/s11255-022-03349-4] [Reference Citation Analysis]
30 Yang T, Kang E, Zhang L, Zhuang J, Li Y, Jiang Y, Wang H, Yu W, Zhang W. Papillary renal neoplasm with reverse polarity may be a novel renal cell tumor entity with low malignant potential. Diagn Pathol 2022;17:66. [PMID: 36002896 DOI: 10.1186/s13000-022-01235-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Lee Y, Park JH, Oh S, Shin K, Sun J, Jung M, Lee C, Kim H, Chung JH, Moon KC, Kwon S. Derivation of prognostic contextual histopathological features from whole-slide images of tumours via graph deep learning. Nat Biomed Eng 2022. [PMID: 35982331 DOI: 10.1038/s41551-022-00923-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Brummer O, Pölönen P, Mustjoki S, Brück O. Integrative Analysis of Histological Textures and Lymphocyte Infiltration in Renal Cell Carcinoma using Deep Learning.. [DOI: 10.1101/2022.08.15.503955] [Reference Citation Analysis]
33 Vivekanandamoorthy N, Moghadam A, Hort A, Howle J. Malignant small bowel obstruction secondary to metastatic renal cell carcinoma with sarcomatoid transformation. Br J Hosp Med 2022;83:1-3. [DOI: 10.12968/hmed.2021.0626] [Reference Citation Analysis]
34 Karagöz A, Guvenis A. Robust whole-tumour 3D volumetric CT-based radiomics approach for predicting the WHO/ISUP grade of a ccRCC tumour. Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization 2022. [DOI: 10.1080/21681163.2022.2103449] [Reference Citation Analysis]
35 Zhou J, Zhao L, Yang Z, Chen Y, Wu X, Xue W. Clinicopathologic, treatment and prognosis study of 46 Xp11.2 translocation/TFE3 gene fusion renal cell carcinomas. BMC Urol 2022;22:109. [PMID: 35850864 DOI: 10.1186/s12894-022-01060-1] [Reference Citation Analysis]
36 Alaghehbandan R, Williamson SR, McKenney JK, Hes O. The Histologic Diversity of Chromophobe Renal Cell Carcinoma With Emphasis on Challenges Encountered in Daily Practice. Adv Anat Pathol 2022;29:194-207. [PMID: 35470289 DOI: 10.1097/PAP.0000000000000349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Samaratunga H, Delahunt B, Yaxley JW, Johannsen S, Egevad L. Intraductal Carcinoma of the Prostate and Nuclear Size. Am J Surg Pathol 2022. [PMID: 35778794 DOI: 10.1097/PAS.0000000000001916] [Reference Citation Analysis]
38 Bukhari I, Khan MR, Hussain MA, Thorne RF, Yu Y, Zhang B, Zheng P, Mi Y. PINTology: A short history of the lncRNA LINC-PINT in different diseases. Wiley Interdiscip Rev RNA 2022;:e1705. [PMID: 35019222 DOI: 10.1002/wrna.1705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Taylor C, Puzyrenko A, Iczkowski KA. Trends in disagreement with outside genitourinary pathology diagnoses at an academic center. Pathol Res Pract 2022;236:153997. [PMID: 35780705 DOI: 10.1016/j.prp.2022.153997] [Reference Citation Analysis]
40 Campi R, Barzaghi P, Pecoraro A, Gallo ML, Stracci D, Mariotti A, Giancane S, Agostini S, Li Marzi V, Sebastianelli A, Spatafora P, Gacci M, Vignolini G, Sessa F, Muiesan P, Serni S. Contemporary techniques and outcomes of surgery for locally advanced renal cell carcinoma with focus on inferior vena cava thrombectomy: the value of a multidisciplinary team. Asian Journal of Urology 2022. [DOI: 10.1016/j.ajur.2022.05.002] [Reference Citation Analysis]
41 Safaei S, Sajed R, Saeednejad Zanjani L, Rahimi M, Fattahi F, Ensieh Kazemi-sefat G, Razmi M, Dorafshan S, Eini L, Madjd Z, Ghods R. Overexpression of cytoplasmic dynamin 2 is associated with worse outcomes in patients with clear cell renal cell carcinoma. CBM 2022. [DOI: 10.3233/cbm-210514] [Reference Citation Analysis]
42 Tabbara MM, Farag A, Ciancio G. Renal cell carcinoma with inferior vena cava tumor thrombus initially misdiagnosed as bland thrombus due to hypercoagulable state. SAGE Open Medical Case Reports 2022;10:2050313X2211020. [DOI: 10.1177/2050313x221102019] [Reference Citation Analysis]
43 Caraballo B, Abdulla M, Sham S, Xiao G, Unger P. Papillary Renal Cell Carcinomas Demonstrating Micropapillary Features: An Investigation Into the Diagnostic and Prognostic Implications. Cureus 2022. [DOI: 10.7759/cureus.24944] [Reference Citation Analysis]
44 Li J, Zhang Q, Guan Y, Liao D, Jiang D, Xiong H, Zhan H, Pang J. Circular RNA circVAMP3 promotes aerobic glycolysis and proliferation by regulating LDHA in renal cell carcinoma. Cell Death Dis 2022;13:443. [PMID: 35525866 DOI: 10.1038/s41419-022-04863-0] [Reference Citation Analysis]
45 Arnold D, Wagener N. 53/m mit bewegungsabhängigen Schmerzen im linken vorderen Becken und blutigem Urin. Onkologe 2022;28:164-171. [DOI: 10.1007/s00761-022-01147-2] [Reference Citation Analysis]
46 Xu P, Zhang S, Cao B, Li Y, Huang J, Lin W, Cheng J, Li H, Chen W, Zhu Y, Jiang S, Hu X, Wu J, Wu Z, Zhou J, Guo J, Wang H. Predictive value of renal tumor contour irregularity score in pathological T3a upstaging of clinical T1 renal cell carcinoma: A multi-institutional study. Urol Oncol 2022;40:199.e1-8. [PMID: 35365414 DOI: 10.1016/j.urolonc.2022.02.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Paner GP, Chumbalkar V, Montironi R, Moch H, Amin MB. Updates in Grading of Renal Cell Carcinomas Beyond Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma. Adv Anat Pathol 2022;29:117-30. [PMID: 35275846 DOI: 10.1097/PAP.0000000000000341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Serzan M, Atkins MB. Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. Expert Rev Anticancer Ther 2022. [PMID: 35483033 DOI: 10.1080/14737140.2022.2072300] [Reference Citation Analysis]
49 Kryvenko ON, Epstein JI. Intraductal Carcinoma of the Prostate: Extreme Nuclear Size Is Not a Diagnostic Parameter. Am J Surg Pathol 2022. [PMID: 35475792 DOI: 10.1097/PAS.0000000000001910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Manini C, López-Fernández E, Lawrie CH, Laruelle A, Angulo JC, López JI. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level. Curr Urol Rep 2022. [PMID: 35416538 DOI: 10.1007/s11934-022-01095-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Di Maida F, Campi R, Lane BR, De Cobelli O, Sanguedolce F, Hatzichristodoulou G, Antonelli A, Grosso AA, Noyes S, Rodriguez-Faba O, Keeley FX, Langenhuijsen J, Musi G, Klatte T, Roscigno M, Akdogan B, Furlan M, Simeone C, Karakoyunlu N, Marszalek M, Capitanio U, Volpe A, Brookman-May S, Gschwend JE, Smaldone MC, Uzzo RG, Kutikov A, Minervini A, Sib International Consortium. Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The Surface-Intermediate-Base Margin Score Consortium). J Clin Med 2022;11:1765. [PMID: 35407375 DOI: 10.3390/jcm11071765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Junker K, Hallscheidt P, Wunderlich H, Hartmann A. Diagnostics and prognostic evaluation in renal cell tumors: the German S3 guidelines recommendations. World J Urol 2022. [PMID: 35294581 DOI: 10.1007/s00345-022-03972-x] [Reference Citation Analysis]
53 Syed M, Loya A, Hameed M, Akhtar N, Mushtaq S, Hassan U. Prognostic Significance of Percentage Necrosis in Clear Cell Renal Cell Carcinoma. Am J Clin Pathol 2022;157:374-80. [PMID: 34643216 DOI: 10.1093/ajcp/aqab136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Fontes-sousa M, Calvo E. First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Ishiyama Y, Kondo T, Ishihara H, Yoshida K, Iizuka J, Tanabe K, Takagi T. C-reactive protein kinetics to predict recurrence of high-risk renal cell carcinoma after radical surgery. Int J Clin Oncol 2022. [PMID: 35150349 DOI: 10.1007/s10147-022-02136-6] [Reference Citation Analysis]
56 Wang J, Chen J, Jiang L, Wu Q, Wang D, Wang J. Predicting Clear Cell Renal Cell Carcinoma Survival Using Kurtosis of Cytoplasm in the Hematoxylin Channel from Histology Slides. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/7693993] [Reference Citation Analysis]
57 Ursprung S, Woitek R, McLean MA, Priest AN, Crispin-Ortuzar M, Brodie CR, Gill AB, Gehrung M, Beer L, Riddick ACP, Field-Rayner J, Grist JT, Deen SS, Riemer F, Kaggie JD, Zaccagna F, Duarte JAG, Locke MJ, Frary A, Aho TF, Armitage JN, Casey R, Mendichovszky IA, Welsh SJ, Barrett T, Graves MJ, Eisen T, Mitchell TJ, Warren AY, Brindle KM, Sala E, Stewart GD, Gallagher FA. Hyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma-A Proof of Principle Study. Cancers (Basel) 2022;14:335. [PMID: 35053497 DOI: 10.3390/cancers14020335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
58 Mattila KE, Vainio P, Jaakkola PM. Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy. Cancers (Basel) 2022;14:239. [PMID: 35008402 DOI: 10.3390/cancers14010239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
59 Goebell PJ. Molekulares Tumorboard – Nierenzellkarzinom. Die Urologie 2022. [DOI: 10.1007/978-3-642-41168-7_252-1] [Reference Citation Analysis]
60 Archard N, Vargiamidou A, Beggan C, Ho-yen CM. Pathological Classification and Biomarkers. Renal Cancer 2022. [DOI: 10.1007/978-3-030-84756-2_5] [Reference Citation Analysis]
61 Mullane PC, Mustafa S, Vandenbussche CJ, Ellis CL. Renal Fine Needle Aspiration and Core Biopsy Specimens: Renal Cell Carcinomas. Genitourinary System Cytology and Small Biopsy Specimens 2022. [DOI: 10.1007/978-3-030-87875-7_5] [Reference Citation Analysis]
62 Sirohi D, Chipman J, Barry M, Albertson D, Mahlow J, Liu T, Raps E, Haaland B, Sayegh N, Li H, Rathi N, Sharma P, Agarwal N, Knudsen B. Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Magi-galluzzi C, Fatima H, Duncan VE, Zhou M. Ureter, Urinary Bladder, and Kidney. Gattuso's Differential Diagnosis in Surgical Pathology 2022. [DOI: 10.1016/b978-0-323-66165-2.00010-7] [Reference Citation Analysis]
64 Murugan P, Jia L, Dinatale RG, Assel M, Benfante N, Al-ahmadie HA, Fine SW, Gopalan A, Sarungbam J, Sirintrapun SJ, Hakimi AA, Russo P, Chen Y, Tickoo SK, Reuter VE. Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. Mod Pathol. [DOI: 10.1038/s41379-021-00990-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
65 Wu J, Zhang R, Gong T, Bao X, Gao Z, Zhang H, Wang C, Li C. A Precision Diagnostic Framework of Renal Cell Carcinoma on Whole-Slide Images using Deep Learning. 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) 2021. [DOI: 10.1109/bibm52615.2021.9669870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Situ Y, Xu Q, Deng L, Zhu Y, Gao R, Lei L, Shao Z. System analysis of VEGFA in renal cell carcinoma: The expression, prognosis, gene regulation network and regulation targets. Int J Biol Markers 2021;:17246008211063501. [PMID: 34870494 DOI: 10.1177/17246008211063501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Kanesvaran R, Porta C, Wong A, Powles T, Ng QS, Schmidinger M, Ye D, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Bhattacharyya GS, Curigliano G, Poon E, Choo SP, Peters S, Lim E, Yoshino T, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO Open 2021;6:100304. [PMID: 34864348 DOI: 10.1016/j.esmoop.2021.100304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Candelario N, Geiger C, Flaig T. Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. KCA 2021;5:167-79. [DOI: 10.3233/kca-210126] [Reference Citation Analysis]
69 Alaghehbandan R, Przybycin CG, Verkarre V, Mehra R. Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates. Asian Journal of Urology 2021. [DOI: 10.1016/j.ajur.2021.11.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Chen S, Jiang L, Gao F, Zhang E, Wang T, Zhang N, Wang X, Zheng J. Machine learning-based pathomics signature could act as a novel prognostic marker for patients with clear cell renal cell carcinoma. Br J Cancer 2021. [PMID: 34824449 DOI: 10.1038/s41416-021-01640-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Xv Y, Lv F, Guo H, Zhou X, Tan H, Xiao M, Zheng Y. Machine learning-based CT radiomics approach for predicting WHO/ISUP nuclear grade of clear cell renal cell carcinoma: an exploratory and comparative study. Insights Imaging 2021;12:170. [PMID: 34800179 DOI: 10.1186/s13244-021-01107-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
72 Sakhadeo U, Yadav SC, Bakshi GK, Prakash G, Katdare A, Menon S, Desai SB. Eosinophilic solid cystic renal cell carcinoma: A series of 3 cases elucidating the spectrum of morphological and clinical features of an emerging new entity. Indian J Urol 2021;37:350-4. [PMID: 34759528 DOI: 10.4103/iju.iju_217_21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Demirjian NL, Varghese BA, Cen SY, Hwang DH, Aron M, Siddiqui I, Fields BKK, Lei X, Yap FY, Rivas M, Reddy SS, Zahoor H, Liu DH, Desai M, Rhie SK, Gill IS, Duddalwar V. CT-based radiomics stratification of tumor grade and TNM stage of clear cell renal cell carcinoma. Eur Radiol 2021. [PMID: 34757449 DOI: 10.1007/s00330-021-08344-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 El Hanbuli HM, Ibrahim HA, Soliman SAM. Immunohistochemical Expression of CD200 in Renal Cell Carcinoma. J Microsc Ultrastruct 2021;9:136-40. [PMID: 34729355 DOI: 10.4103/JMAU.JMAU_29_20] [Reference Citation Analysis]
75 . Renal Tumors of Adults. Tumors of the Kidney, Bladder, and Related Urinary Structures 2021. [DOI: 10.55418/9781933477176-2] [Reference Citation Analysis]
76 Gad S, Le Teuff G, Nguyen B, Verkarre V, Duchatelle V, Molinie V, Posseme K, Grandon B, Da Costa M, Job B, Meurice G, Droin N, Mejean A, Couve S, Renaud F, Gardie B, Teh BT, Richard S, Ferlicot S. Involvement of PBRM1 in VHL disease-associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway. Oncol Lett 2021;22:835. [PMID: 34712359 DOI: 10.3892/ol.2021.13096] [Reference Citation Analysis]
77 Tsili AC, Moulopoulos LA, Varakarakis IΜ, Argyropoulou MI. Cross-sectional imaging assessment of renal masses with emphasis on MRI. Acta Radiol 2021;:2841851211052999. [PMID: 34709096 DOI: 10.1177/02841851211052999] [Reference Citation Analysis]
78 Kubiliute R, Zalimas A, Bakavicius A, Ulys A, Jankevicius F, Jarmalaite S. Clinical Significance of ADAMTS19, BMP7, SIM1, and SFRP1 Promoter Methylation in Renal Clear Cell Carcinoma. Onco Targets Ther 2021;14:4979-90. [PMID: 34675538 DOI: 10.2147/OTT.S330341] [Reference Citation Analysis]
79 Kubiliūtė R, Žukauskaitė K, Žalimas A, Ulys A, Sabaliauskaitė R, Bakavičius A, Želvys A, Jankevičius F, Jarmalaitė S. Clinical significance of novel DNA methylation biomarkers for renal clear cell carcinoma. J Cancer Res Clin Oncol 2021. [PMID: 34689221 DOI: 10.1007/s00432-021-03837-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Ma G, Wang Z, Liu J, Fu S, Zhang L, Zheng D, Shang P, Yue Z. Quantitative proteomic analysis reveals sophisticated metabolic alteration and identifies FMNL1 as a prognostic marker in clear cell renal cell carcinoma. J Cancer 2021;12:6563-75. [PMID: 34659547 DOI: 10.7150/jca.62309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Guo P, Wang Y, Han Y, Wei D, Zhao J, Li M, Jiang Y, Luo Y. Development and validation of a nomogram to predict postoperative cancer-specific survival of patients with nonmetastatic T3a renal cell carcinoma. Urol Oncol 2021;39:835.e19-27. [PMID: 34620554 DOI: 10.1016/j.urolonc.2021.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Lobo J, Ohashi R, Helmchen BM, Rupp NJ, Rüschoff JH, Moch H. The Morphological Spectrum of Papillary Renal Cell Carcinoma and Prevalence of Provisional/Emerging Renal Tumor Entities with Papillary Growth. Biomedicines 2021;9:1418. [PMID: 34680535 DOI: 10.3390/biomedicines9101418] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
83 Xiong S, Zhu W, Li X, Yu Y, Yang K, Zhang L, Mi Y, Li X, Zhou L. Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis. Transl Androl Urol 2021;10:3255-66. [PMID: 34532250 DOI: 10.21037/tau-21-329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Yang C, Shuch B, Kluger HM, Serrano M, Kibel AS, Humphrey PA, Adeniran AJ. Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. Am J Clin Pathol 2021;156:550-8. [PMID: 34424955 DOI: 10.1093/ajcp/aqab015] [Reference Citation Analysis]
85 Polifka I, Ohashi R, Moch H. [Oncocytic tumours of the kidney-new differential diagnoses]. Pathologe 2021;42:551-9. [PMID: 34468818 DOI: 10.1007/s00292-021-00979-w] [Reference Citation Analysis]
86 Wang X, Song G, Jiang H, Zheng L, Pang P, Xu J. Can texture analysis based on single unenhanced CT accurately predict the WHO/ISUP grading of localized clear cell renal cell carcinoma? Abdom Radiol (NY) 2021;46:4289-300. [PMID: 33909090 DOI: 10.1007/s00261-021-03090-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
87 Haji-Momenian S, Ricker R, Chen Z, Houser M, Adusumilli N, Yang M, Toubaji A, Loew M. Prediction of histologic grade and type of small (< 4 cm) papillary renal cell carcinomas using texture and neural network analysis: a feasibility study. Abdom Radiol (NY) 2021;46:4266-77. [PMID: 33813624 DOI: 10.1007/s00261-021-03044-5] [Reference Citation Analysis]
88 Browning L, Colling R, Verrill C. WHO/ISUP grading of clear cell renal cell carcinoma and papillary renal cell carcinoma; validation of grading on the digital pathology platform and perspectives on reproducibility of grade. Diagn Pathol 2021;16:75. [PMID: 34419085 DOI: 10.1186/s13000-021-01130-2] [Reference Citation Analysis]
89 Nguyen JK, Mckenney JK, Williamson SR. Clinical utility of pathology data: prostate and kidney cancer. Diagnostic Histopathology 2021;27:297-304. [DOI: 10.1016/j.mpdhp.2021.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
90 Zhang X, Guo X, Zong Y, Xu C, Wang J, Zhang B, Liu C, Gong Y, Xue L, Ma L, Zhang S, Li Y, Zeng H. CTCs detection from intraoperative salvaged blood in RCC-IVC thrombus patients by negative enrichment and iFISH identification: a preliminary study. BMC Urol 2021;21:89. [PMID: 34112129 DOI: 10.1186/s12894-021-00803-w] [Reference Citation Analysis]
91 Su X, Hou NN, Yang LJ, Li PX, Yang XJ, Hou GD, Gao XL, Ma SJ, Guo F, Zhang R, Zhang WH, Qin WJ, Wang FL. The first competing risk survival nomogram in patients with papillary renal cell carcinoma. Sci Rep 2021;11:11835. [PMID: 34088935 DOI: 10.1038/s41598-021-91217-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
92 Bersanelli M, Buti S, Gnetti L, Varotti E, Carbognani P, Rusca M, Leonardi F, Campanini N, Ziglioli F, Dadomo CI, Pilato FP, Ventura L, Braggio C, Bocchialini G, Cortellini A, Brunelli M, Rapacchi E, Camisa R, Caruso G, Silini EM, Maestroni U, Ampollini L. Pulmonary metastasectomy in renal cell carcinoma: Predictive and prognostic elements from paired histopathological analysis of primary tumors and respective metastases. Journal of Onco-Nephrology 2021;5:96-104. [DOI: 10.1177/23993693211028593] [Reference Citation Analysis]
93 Zhou Z, Qian X, Hu J, Ma X, Zhou S, Dai Y, Zhu J. CT-based peritumoral radiomics signatures for malignancy grading of clear cell renal cell carcinoma. Abdom Radiol (NY) 2021;46:2690-8. [PMID: 33427908 DOI: 10.1007/s00261-020-02890-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Campi R, Sessa F, Rivetti A, Pecoraro A, Barzaghi P, Morselli S, Polverino P, Nicoletti R, Li Marzi V, Spatafora P, Sebastianelli A, Gacci M, Vignolini G, Serni S. Case Report: Optimizing Pre- and Intraoperative Planning With Hyperaccuracy Three-Dimensional Virtual Models for a Challenging Case of Robotic Partial Nephrectomy for Two Complex Renal Masses in a Horseshoe Kidney. Front Surg 2021;8:665328. [PMID: 34136528 DOI: 10.3389/fsurg.2021.665328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
95 Abdul-Ghafar J, Ud Din N, Saadaat R, Ahmad Z. Metastatic renal cell carcinoma to pancreas and gastrointestinal tract: a clinicopathological study of 3 cases and review of literature. BMC Urol 2021;21:84. [PMID: 34034720 DOI: 10.1186/s12894-021-00854-z] [Reference Citation Analysis]
96 Park JS, Lee ME, Jang WS, Rha KH, Lee SH, Lee J, Ham WS. The DEAD/DEAH Box Helicase, DDX11, Is Essential for the Survival of Advanced Clear Cell Renal Cell Carcinoma and Is a Determinant of PARP Inhibitor Sensitivity. Cancers (Basel) 2021;13:2574. [PMID: 34073906 DOI: 10.3390/cancers13112574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
97 Karagoz A, Guvenis A. Predicting the Grade of Clear Cell Renal Cell Carcinoma from CT Images Using Random Subspace-KNN and Random Forest Classifiers. 2021 Ural Symposium on Biomedical Engineering, Radioelectronics and Information Technology (USBEREIT) 2021. [DOI: 10.1109/usbereit51232.2021.9455032] [Reference Citation Analysis]
98 Mattila KE, Laajala TD, Tornberg SV, Kilpeläinen TP, Vainio P, Ettala O, Boström PJ, Nisen H, Elo LL, Jaakkola PM. A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. Sci Rep 2021;11:8650. [PMID: 33883645 DOI: 10.1038/s41598-021-88177-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
99 Neves JB, Vanaclocha Saiz L, Abu-Ghanem Y, Marchetti M, Tran-Dang MA, El-Sheikh S, Barod R, Beisland C, Capitanio U, Cullen D, Klatte T, Ljungberg B, Mumtaz F, Patki P, Stewart GD, Dabestani S, Tran MGB, Bex A; RECUR consortium. Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. World J Urol 2021. [PMID: 33851271 DOI: 10.1007/s00345-021-03683-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Polifka I, Agaimy A, Moch H, Hartmann A. [Histological subtypes of renal cell carcinoma : Overview and new developments]. Pathologe 2021;42:294-304. [PMID: 33825093 DOI: 10.1007/s00292-021-00937-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Park JS, Jang WS, Kim J, Lee SH, Rha KH, Ham WS. Association between visceral adiposity and DDX11 as a predictor of aggressiveness of small clear-cell renal-cell carcinoma: a prospective clinical trial. Cancer Metab 2021;9:15. [PMID: 33823929 DOI: 10.1186/s40170-021-00251-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Sali AP, Bahirwade GK, Bakshi G, Prakash G, Joshi A, Desai SB, Menon S. Application and comparison of Fuhrman nuclear grading system with the novel tumor grading system for chromophobe renal cell carcinoma and its correlation with disease-specific events. Indian J Urol 2021;37:147-52. [PMID: 34103797 DOI: 10.4103/iju.IJU_633_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Tessier-Cloutier B, Twa DD, Marzban M, Kalina J, Chun HE, Pavey N, Tanweer Z, Katz RL, Lum JJ, Salina D. The presence of tumour-infiltrating neutrophils is an independent adverse prognostic feature in clear cell renal cell carcinoma. J Pathol Clin Res 2021;7:385-96. [PMID: 33665979 DOI: 10.1002/cjp2.204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
104 Khauli M, Heidar NA, Degheili JA, Hakam N, Al-Moussawy M, Shahait M, El-Asmar J, Bustros G, Merhe A, Nasr R, Bulbul M, Wazzan W, El-Hajj A, Shamseddine A, Kfoury H, Mukherji D, Khauli R. Comparative analysis of histopathological subtypes of renal cell carcinoma in the Middle East compared to other world regions. Urol Ann 2021;13:130-3. [PMID: 34194138 DOI: 10.4103/UA.UA_172_20] [Reference Citation Analysis]
105 Trpkov K, Hes O, Williamson SR, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen YB, Cheng L, Epstein JI, Cheville JC, Comperat E, da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, Humphrey PA, Kapur P, Kojima F, Lopez JI, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Gill AJ. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol 2021;34:1392-424. [PMID: 33664427 DOI: 10.1038/s41379-021-00779-w] [Cited by in Crossref: 71] [Cited by in F6Publishing: 79] [Article Influence: 35.5] [Reference Citation Analysis]
106 Rabjerg M, Gerke O, Engvad B, Marcussen N. Comparing World Health Organization/International Society of Urological Pathology Grading and Fuhrman Grading with the Prognostic Value of Nuclear Area in Patients with Renal Cell Carcinoma. Uro 2021;1:2-13. [DOI: 10.3390/uro1010002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant'Angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-Ivins M, Hirsch L, Baca SC, Wind-Rotolo M, Ross-Macdonald P, Sun M, Lee GM, Chang SL, Wei XX, McGregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, McDermott DF, Heng DYC, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun 2021;12:808. [PMID: 33547292 DOI: 10.1038/s41467-021-21068-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
108 Athanazio DA, Amorim LS, da Cunha IW, Leite KRM, da Paz AR, de Paula Xavier Gomes R, Tavora FRF, Faraj SF, Cavalcanti MS, Bezerra SM. Classification of renal cell tumors – current concepts and use of ancillary tests: recommendations of the Brazilian Society of Pathology. Surg Exp Pathol 2021;4. [DOI: 10.1186/s42047-020-00084-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
109 Kundu A, Sen A, Choudhury S, Mandal TK, Guha D, Lahiry S. Immunohistochemical analysis of beta-catenin expression: a probable prognostic marker and potential therapeutic target in renal cell carcinoma. Med Pharm Rep 2021;94:65-72. [PMID: 33629051 DOI: 10.15386/mpr-1767] [Reference Citation Analysis]
110 Yi X, Xiao Q, Zeng F, Yin H, Li Z, Qian C, Wang C, Lei G, Xu Q, Li C, Li M, Gong G, Zee C, Guan X, Liu L, Chen BT. Computed Tomography Radiomics for Predicting Pathological Grade of Renal Cell Carcinoma. Front Oncol 2020;10:570396. [PMID: 33585193 DOI: 10.3389/fonc.2020.570396] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
111 Kuroe T, Watanabe R, Kojima M, Morisue R, Sugano M, Kuwata T, Masuda H, Kusuhara S, Matsubara N, Oda S, Ushiku T, Ishii G. Evaluation of the morphological features and unfavorable prognostic impact of dirty necrosis in renal cell carcinoma. J Cancer Res Clin Oncol 2021;147:1089-100. [PMID: 33475860 DOI: 10.1007/s00432-020-03505-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Zhu J, Liu Z, Zhang Z, Fan Y, Chen Y, He Z, Zhou L, Jin J, Shen C, Yu W. Development and internal validation of nomograms for the prediction of postoperative survival of patients with grade 4 renal cell carcinoma (RCC). Transl Androl Urol 2020;9:2629-39. [PMID: 33457235 DOI: 10.21037/tau-19-687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Gao Z, Shi J, Zhang X, Li Y, Zhang H, Wu J, Wang C, Meng D, Li C. Nuclei Grading of Clear Cell Renal Cell Carcinoma in Histopathological Image by Composite High-Resolution Network. Medical Image Computing and Computer Assisted Intervention – MICCAI 2021 2021. [DOI: 10.1007/978-3-030-87237-3_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Alaghehbandan R, Trpkov K, Tretiakova M, Luis AS, Rogala JD, Hes O. Comprehensive Review of Numerical Chromosomal Aberrations in Chromophobe Renal Cell Carcinoma Including Its Variant Morphologies. Adv Anat Pathol 2021;28:8-20. [PMID: 33021507 DOI: 10.1097/PAP.0000000000000286] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
115 Tretiakova M, Williamson SR. Kidney Tumor. Practical Genitourinary Pathology 2021. [DOI: 10.1007/978-3-030-57141-2_1] [Reference Citation Analysis]
116 Gao Z, Hong B, Zhang X, Li Y, Jia C, Wu J, Wang C, Meng D, Li C. Instance-Based Vision Transformer for Subtyping of Papillary Renal Cell Carcinoma in Histopathological Image. Medical Image Computing and Computer Assisted Intervention – MICCAI 2021 2021. [DOI: 10.1007/978-3-030-87237-3_29] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
117 Grubb W, Lo S, Ellis R, Louie A, Teh B, Siva S. Radiation Therapy for Renal Cell Carcinoma. Practical Guides in Radiation Oncology 2021. [DOI: 10.1007/978-3-030-65137-4_13] [Reference Citation Analysis]
118 Xiao Q, Yi X, Guan X, Yin H, Wang C, Zhang L, Pang Y, Li M, Gong G, Chen D, Liu L. Validation of the World Health Organization/International Society of Urological Pathology grading for Chinese patients with clear cell renal cell carcinoma. Transl Androl Urol 2020;9:2665-74. [PMID: 33457238 DOI: 10.21037/tau-20-799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
119 Nini A, Muttin F, Cianflone F, Carenzi C, Luciano R, Catena M, Larcher A, Salvioni M, Cazzaniga W, Pederzoli F, Matloob R, Colombo R, Paganelli M, Salonia A, Briganti A, Doglioni C, Zangrillo A, DE Cobelli F, Rigatti P, Freschi M, Cornero G, Nicoletti R, Aldrighetti L, Montorsi F, Capitanio U, Bertini R. Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. Minerva Urol Nephrol 2021;73:746-53. [PMID: 33242949 DOI: 10.23736/S2724-6051.20.03844-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
120 Reese B, Silwal A, Daugherity E, Daugherity M, Arabi M, Daly P, Paterson Y, Woolford L, Christie A, Elias R, Brugarolas J, Wang T, Karbowniczek M, Markiewski MM. Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma. J Immunol 2020;205:3218-29. [PMID: 33158953 DOI: 10.4049/jimmunol.2000511] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
121 Zhi H, Feng M, Liu S, Na T, Zhang N, BiLiGe W. Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:591001. [PMID: 33134181 DOI: 10.3389/fonc.2020.591001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
122 Xu K, Liu L, Li W, Sun X, Shen T, Pan F, Jiang Y, Guo Y, Ding L, Zhang M. CT-Based Radiomics Signature for Preoperative Prediction of Coagulative Necrosis in Clear Cell Renal Cell Carcinoma. Korean J Radiol 2020;21:670-83. [PMID: 32410406 DOI: 10.3348/kjr.2019.0607] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
123 Seçinti İE, Akincioğlu E, Kandemir O. Beclin 1 (otofaji belirteci), p53 mutasyonu, Ki-67 proliferasyon indeksi, tümör nekrozu ve mikrovasküler invazyonun böbrek hücreli karsinomlarda prognoz üzerindeki etkisi ve bunların bilinen prognostik parametrelerle ilişkisi. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi 2020. [DOI: 10.17517/ksutfd.794679] [Reference Citation Analysis]
124 Takeda K, Murray G, Vohra N, Fallon JT. A case of the world's largest renal cell carcinoma. IJU Case Rep 2021;4:49-52. [PMID: 33426498 DOI: 10.1002/iju5.12236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
125 Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
126 Buchler T. VENUSS rising for papillary renal cell carcinoma prognostication? Ann Transl Med 2020;8:1036. [PMID: 32953836 DOI: 10.21037/atm.2020.03.216] [Reference Citation Analysis]
127 Nahouraii LM, Allen JL, Merrill SB, Lehman E, Kaag MG, Raman JD. Histologic Heterogeneity of Extirpated Renal Cell Carcinoma Specimens: Implications for Renal Mass Biopsy. J Kidney Cancer VHL 2020;7:20-5. [PMID: 32953423 DOI: 10.15586/jkcvhl.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
128 Le X, Wang XB, Zhao H, Chen RF, Ge P. Comparison of clinicopathologic parameters and oncologic outcomes between type 1 and type 2 papillary renal cell carcinoma. BMC Urol 2020;20:148. [PMID: 32933514 DOI: 10.1186/s12894-020-00716-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
129 Eraslan E, Yalçintaş Ü. Long-term follow-up results of patients with sarcomatoid RCC: A retrospective evaluation of a single center experience. Journal of Surgery and Medicine 2020;4:803-807. [DOI: 10.28982/josam.789516] [Reference Citation Analysis]
130 Zhao Y, Wu C, Li W, Chen X, Li Z, Liao X, Cui Y, Zhao G, Liu M, Fu Z. 2-[18F]FDG PET/CT parameters associated with WHO/ISUP grade in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 2021;48:570-9. [PMID: 32814979 DOI: 10.1007/s00259-020-04996-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
131 Sweigert SE, Bajic P, Aragao A, Picken M, Woods ME. Renal Cell Carcinoma with Direct Extension into the Gonadal Vein, Uterus, Fallopian Tube, and Bilateral Ovaries: A Case Report. J Kidney Cancer VHL 2020;7:1-4. [PMID: 32953420 DOI: 10.15586/jkcvhl.2020.130] [Reference Citation Analysis]
132 Han D, Yu Y, Yu N, Dang S, Wu H, Jialiang R, He T. Prediction models for clear cell renal cell carcinoma ISUP/WHO grade: comparison between CT radiomics and conventional contrast-enhanced CT. Br J Radiol 2020;93:20200131. [PMID: 32706977 DOI: 10.1259/bjr.20200131] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
133 Steinberg RL, Rasmussen RG, Johnson BA, Ghandour R, De Leon AD, Xi Y, Yokoo T, Kim S, Kapur P, Cadeddu JA, Pedrosa I. Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging. Eur Radiol 2021;31:314-24. [PMID: 32770377 DOI: 10.1007/s00330-020-07093-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
134 Meng X, Shu J, Xia Y, Yang R. A CT-Based Radiomics Approach for the Differential Diagnosis of Sarcomatoid and Clear Cell Renal Cell Carcinoma. Biomed Res Int 2020;2020:7103647. [PMID: 32775436 DOI: 10.1155/2020/7103647] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
135 Mourão TC, Abreu D, Carvalhal GF, Gueglio G, da Costa WH, Calsavara VF, Meza-Montoya L, Bengió RG, Scorticati C, Castillejos-Molina R, Rodríguez-Covarrubias F, Autran-Gómez AM, Campos-Salcedo JG, Nolazco A, Ameri C, Zampolli H, Langenhin R, Muguruza D, Machado MT, Mingote P, Clavijo J, Nogueira L, Clark O, Rovegno AR, Secin FP, Decia R, Guimarães GC, Glina S, Rodríguez-Faba O, Palou J, Zequi SC. Small renal masses in Latin-American population: characteristics and prognostic factors for survival, recurrence and metastasis - a multi-institutional study from LARCG database. BMC Urol 2020;20:85. [PMID: 32615971 DOI: 10.1186/s12894-020-00649-8] [Reference Citation Analysis]
136 Ling YH, Chen JW, Wen SH, Huang CY, Li P, Lu LH, Mei J, Li SH, Wei W, Cai MY, Guo RP. Tumor necrosis as a poor prognostic predictor on postoperative survival of patients with solitary small hepatocellular carcinoma. BMC Cancer 2020;20:607. [PMID: 32600297 DOI: 10.1186/s12885-020-07097-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
137 Li J, Jiang D, Zhang Q, Peng S, Liao G, Yang X, Tang J, Xiong H, Pang J. MiR-301a Promotes Cell Proliferation by Repressing PTEN in Renal Cell Carcinoma. Cancer Manag Res 2020;12:4309-20. [PMID: 32606927 DOI: 10.2147/CMAR.S253533] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
138 Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Alaiwi SA, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant’angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-ivins M, Hirsch L, Wind-rotolo M, Ross-macdonald P, Sun M, Lee GM, Chang SL, Wei XX, Mcgregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, Mcdermott DF, Heng DY, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint Inhibitors.. [DOI: 10.1101/2020.05.28.121806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Jiang Y, Li W, Huang C, Tian C, Chen Q, Zeng X, Cao Y, Chen Y, Yang Y, Liu H, Bo Y, Luo C, Li Y, Zhang T, Wang R. A Computed Tomography-Based Radiomics Nomogram to Preoperatively Predict Tumor Necrosis in Patients With Clear Cell Renal Cell Carcinoma. Front Oncol 2020;10:592. [PMID: 32547934 DOI: 10.3389/fonc.2020.00592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
140 Bersanelli M, Brunelli M, Gnetti L, Maestroni U, Buti S. Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review. Ther Adv Med Oncol 2020;12:1758835920915303. [PMID: 32550862 DOI: 10.1177/1758835920915303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
141 Argentiero A, Solimando AG, Krebs M, Leone P, Susca N, Brunetti O, Racanelli V, Vacca A, Silvestris N. Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. J Clin Med 2020;9:E1594. [PMID: 32456352 DOI: 10.3390/jcm9051594] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
142 Park JS, Lee HJ, Almujalhem A, Althubiany HH, A AA, Jang WS, Kim J, Lee SH, Rha KH, Ham WS. Prediction of High-Grade Clear Cell Renal Cell Carcinoma Based on Plasma mRNA Profiles in Patients with Localized Pathologic T1N0M0 Stage Disease. Cancers (Basel) 2020;12:E1182. [PMID: 32392781 DOI: 10.3390/cancers12051182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
143 Kawashima A, Kanazawa T, Kidani Y, Yoshida T, Hirata M, Nishida K, Nojima S, Yamamoto Y, Kato T, Hatano K, Ujike T, Nagahara A, Fujita K, Morimoto-Okazawa A, Iwahori K, Uemura M, Imamura R, Ohkura N, Morii E, Sakaguchi S, Wada H, Nonomura N. Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. Sci Rep 2020;10:6220. [PMID: 32277125 DOI: 10.1038/s41598-020-63060-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
144 Haji-Momenian S, Lin Z, Patel B, Law N, Michalak A, Nayak A, Earls J, Loew M. Texture analysis and machine learning algorithms accurately predict histologic grade in small (< 4 cm) clear cell renal cell carcinomas: a pilot study. Abdom Radiol (NY) 2020;45:789-98. [PMID: 31822969 DOI: 10.1007/s00261-019-02336-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
145 Sánchez-magraner L, Miles J, Baker C, Applebee CJ, Lee D, Elsheikh S, Lashin S, Withers K, Watts A, Parry R, Edmead C, Lopez JI, Mehta R, Ward SG, Parker PJ, Larijani B. Immune-checkpoint engagement as predictive biomarkers in clear cell renal cell carcinoma and melanoma.. [DOI: 10.1101/2020.01.15.20017517] [Reference Citation Analysis]
146 O’rourke D. Renal Cell and Renal Pelvis/Ureter Carcinoma. Histopathology Reporting 2020. [DOI: 10.1007/978-3-030-27828-1_29] [Reference Citation Analysis]
147 Caliò A, Segala D, Martignoni G. Clear Cell Renal Cell Carcinoma. Encyclopedia of Pathology 2020. [DOI: 10.1007/978-3-030-41894-6_4792] [Reference Citation Analysis]
148 de Lima Guido LP, Hanly F, Escobedo B, Jorda M, Pinto A. Pathological Interpretation of Renal Mass Biopsies. Renal Mass Biopsy 2020. [DOI: 10.1007/978-3-030-36036-8_8] [Reference Citation Analysis]
149 Lowe AC. Kidney, Adrenal Gland, and Retroperitoneum. Practical Cytopathology 2020. [DOI: 10.1007/978-3-030-24059-2_18] [Reference Citation Analysis]
150 Francis F, Zhou M. Pathology of Renal Cell Carcinoma. Renal Cancer 2020. [DOI: 10.1007/978-3-030-24378-4_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
151 Lopez-beltran A, Raspollini MR, Cheng L, Scarpelli M, Cimadamore A, Santoni M, Gasparrini S, Montironi R. Staging and Reporting of Renal Cell Carcinomas. Kidney Cancer 2020. [DOI: 10.1007/978-3-030-28333-9_21] [Reference Citation Analysis]
152 Renshaw AA. Fine Needle Aspiration of the Kidney. Urologic Surgical Pathology 2020. [DOI: 10.1016/b978-0-323-54941-7.00004-9] [Reference Citation Analysis]
153 Gao Z, Puttapirat P, Shi J, Li C. Renal Cell Carcinoma Detection and Subtyping with Minimal Point-Based Annotation in Whole-Slide Images. Medical Image Computing and Computer Assisted Intervention – MICCAI 2020 2020. [DOI: 10.1007/978-3-030-59722-1_42] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
154 Potić-floranović M, Ristić-petrović A, Veličković F, Potić M, Džopalić T, Janković-veličković L. Rhabdoid differentiation in different types of renal cell carcinoma: A report of two cases and literature review. Acta fac medic Naissensis 2020;37:79-86. [DOI: 10.5937/afmnai2001079p] [Reference Citation Analysis]
155 Divatia MK, Guo CC, Rehman A, Ro JY. Major Subtypes of Renal Cell Carcinoma. Kidney Cancer 2020. [DOI: 10.1007/978-3-030-28333-9_5] [Reference Citation Analysis]
156 Maclennan GT, Cheng L. Neoplasms of the Kidney. Urologic Surgical Pathology 2020. [DOI: 10.1016/b978-0-323-54941-7.00002-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
157 Feng Z, Lou S, Zhang L, Zhang L, Lan W, Wang M, Shen Q, Hu Z, Chen F. New Preoperative Nomogram Using the Centrality Index to Predict High Nuclear Grade Clear Cell Renal Carcinoma. Cancer Manag Res 2019;11:10921-8. [PMID: 32099456 DOI: 10.2147/CMAR.S229571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
158 van Oostenbrugge TJ, Langenhuijsen JF, Fütterer JJ, Mulders PF. The Value of Multiparametric MRI for Assessment of Inferior Vena Cava Wall Invasion by Renal Cell Carcinoma Thrombus: A Prospective Feasibility Study. KCA 2019;3:227-33. [DOI: 10.3233/kca-190071] [Reference Citation Analysis]
159 Shi S, Ye S, Wu X, Xu M, Zhuo R, Liao Q, Xi Y. A Two-DNA Methylation Signature to Improve Prognosis Prediction of Clear Cell Renal Cell Carcinoma. Yonsei Med J 2019;60:1013-20. [PMID: 31637882 DOI: 10.3349/ymj.2019.60.11.1013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
160 Nesiu A, Cimpean AM, Ceausu RA, Adile A, Ioiart I, Porta C, Mazzanti M, Camerota TC, Raica M. Intracellular Chloride Ion Channel Protein-1 Expression in Clear Cell Renal Cell Carcinoma. Cancer Genomics Proteomics 2019;16:299-307. [PMID: 31243111 DOI: 10.21873/cgp.20135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
161 Kadomoto S, Makino T, Izumi K, Mizokami A. An important step in establishing a treatment strategy for small renal masses of clear cell renal cell carcinoma based on the significance of adverse histopathologic features on tumor needle biopsy. Ann Transl Med 2019;7:S374. [PMID: 32016092 DOI: 10.21037/atm.2019.12.104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Jia K, Wu Y, Huang J, Wu H. Survival-Associated Alternative Splicing Events in Pan-Renal Cell Carcinoma. Front Oncol 2019;9:1317. [PMID: 31850211 DOI: 10.3389/fonc.2019.01317] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
163 Ohashi R, Martignoni G, Hartmann A, Caliò A, Segala D, Stöhr C, Wach S, Erlmeier F, Weichert W, Autenrieth M, Schraml P, Rupp NJ, Ohe C, Otsuki Y, Kawasaki T, Kobayashi H, Kobayashi K, Miyazaki T, Shibuya H, Usuda H, Umezu H, Fujishima F, Furusato B, Osakabe M, Sugai T, Kuroda N, Tsuzuki T, Nagashima Y, Ajioka Y, Moch H. Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Arch 2020;476:409-18. [PMID: 31760491 DOI: 10.1007/s00428-019-02710-w] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
164 Staehler M, Goebell PJ, Müller L, Emde TO, Wetzel N, Kruggel L, Jänicke M, Marschner N; RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma). Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry. Int J Cancer 2020;146:1307-15. [PMID: 31498894 DOI: 10.1002/ijc.32671] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
165 Jouini R, Saidi A, Khanchel F, Helal I, Chtourou M, Chadli-Debbiche A. Sarcomatoid chromophobe renal cell carcinoma revealed by acute pyelonephritis in a diabetic patient. Urol Case Rep 2020;28:101037. [PMID: 31681535 DOI: 10.1016/j.eucr.2019.101037] [Reference Citation Analysis]
166 Shi J, Gao Z, Zhang H, Puttapirat P, Wang C, Zhang X, Li C. Effects of annotation granularity in deep learning models for histopathological images. 2019 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) 2019. [DOI: 10.1109/bibm47256.2019.8983158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
167 Klatte T, Gallagher KM, Afferi L, Volpe A, Kroeger N, Ribback S, McNeill A, Riddick ACP, Armitage JN, 'Aho TF, Eisen T, Fife K, Bex A, Pantuck AJ, Stewart GD. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. BMC Med 2019;17:182. [PMID: 31578141 DOI: 10.1186/s12916-019-1419-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
168 Tian K, Rubadue CA, Lin DI, Veta M, Pyle ME, Irshad H, Heng YJ. Automated clear cell renal carcinoma grade classification with prognostic significance. PLoS One 2019;14:e0222641. [PMID: 31581201 DOI: 10.1371/journal.pone.0222641] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
169 Chandrasekaran D, Sundaram S, N K, R P. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma. Asian Pac J Cancer Prev 2019;20:2951-7. [PMID: 31653140 DOI: 10.31557/APJCP.2019.20.10.2951] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
170 Sellner F. Observations on Solitary Versus Multiple Isolated Pancreatic Metastases of Renal Cell Carcinoma: Another Indication of a Seed and Soil Mechanism? Cancers (Basel) 2019;11:E1379. [PMID: 31533220 DOI: 10.3390/cancers11091379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
171 Salmond JM. Pathology of tumours of the kidney and urinary tract. Surgery (Oxford) 2019;37:481-486. [DOI: 10.1016/j.mpsur.2019.07.005] [Reference Citation Analysis]
172 Devrim T. BÖBREK TÜMÖRÜ VAKALARININ RETROSPEKTİF OLARAK DEĞERLENDİRİLMESİ. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi 2019. [DOI: 10.24938/kutfd.552211] [Reference Citation Analysis]
173 Tu X, Wang F, Chang T, Zhang C, Zhang M, Liu Z, Qiu S, Yang L, Wei Q. Predictive value of preoperative neutrophil-to-lymphocyte ratio in non-metastatic papillary renal cell carcinoma patients after receiving curative surgery. Cancer Manag Res 2019;11:7515-24. [PMID: 31496809 DOI: 10.2147/CMAR.S211727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
174 Moran K, Abreu-Gomez J, Krishna S, Flood TA, Walker D, McInnes MDF, Schieda N. Can MRI be used to diagnose histologic grade in T1a (< 4 cm) clear cell renal cell carcinomas? Abdom Radiol (NY) 2019;44:2841-51. [PMID: 31041495 DOI: 10.1007/s00261-019-02018-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
175 Duan J, Ma X, Shi J, Xuan Y, Wang H, Li P, Zhang Y, Fan Y, Gong H, Ma X, Pang Y, Wang L, Yan Y, Zhang X. Long noncoding RNA LINC-PINT promotes proliferation through EZH2 and predicts poor prognosis in clear cell renal cell carcinoma. Onco Targets Ther 2019;12:4729-40. [PMID: 31417274 DOI: 10.2147/OTT.S202938] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
176 Gao Z, Man X, Li Z, Bi J, Liu X, Li Z, Li J, Zhang Z, Kong C. PLK1 promotes proliferation and suppresses apoptosis of renal cell carcinoma cells by phosphorylating MCM3. Cancer Gene Ther 2020;27:412-23. [PMID: 31186514 DOI: 10.1038/s41417-019-0094-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
177 Tian K, Rubadue CA, Lin DI, Veta M, Pyle ME, Irshad H, Heng YJ. Automated Clear Cell Renal Carcinoma Grade Classification with Prognostic Significance.. [DOI: 10.1101/661520] [Reference Citation Analysis]
178 Erlmeier F, Agaimy A, Hartmann A, Stöhr CG. Pathologie und Molekularpathologie des Nierenzellkarzinoms. Onkologe 2019;25:497-511. [DOI: 10.1007/s00761-019-0571-8] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
179 Borys AM, Seweryn M, Gołąbek T, Bełch Ł, Klimkowska A, Totoń-Żurańska J, Machlowska J, Chłosta P, Okoń K, Wołkow PP. Patterns of gene expression characterize T1 and T3 clear cell renal cell carcinoma subtypes. PLoS One 2019;14:e0216793. [PMID: 31150395 DOI: 10.1371/journal.pone.0216793] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
180 Guo C, Zhao H, Wang Y, Bai S, Yang Z, Wei F, Ren X. Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma. Front Oncol 2019;9:439. [PMID: 31192136 DOI: 10.3389/fonc.2019.00439] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
181 Liu N, Gan W, Qu F, Wang Z, Zhuang W, Agizamhan S, Xu L, Yin J, Guo H, Li D. Does the Fuhrman or World Health Organization/International Society of Urological Pathology Grading System Apply to the Xp11.2 Translocation Renal Cell Carcinoma?: A 10-Year Single-Center Study. Am J Pathol 2018;188:929-36. [PMID: 29571325 DOI: 10.1016/j.ajpath.2017.12.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
182 Delahunt B, Eble JN, Egevad L, Yaxley J, Thunders M, Samaratunga H. Emerging entities of renal cell neoplasia. Surg Exp Pathol 2019;2. [DOI: 10.1186/s42047-019-0035-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
183 Pichler R, Compérat E, Klatte T, Pichler M, Loidl W, Lusuardi L, Schmidinger M. Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope? Cancers (Basel) 2019;11:E422. [PMID: 30934624 DOI: 10.3390/cancers11030422] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
184 Hendry J, Rai BP, Mcneill AS, Nabi G, Stolzenburg J, Qureshi K, Umez‐eronini N, Oades G, Aboumarzouk OM. Kidney and Ureter Neoplasm. Blandy's Urology 2019. [DOI: 10.1002/9781118863343.ch13] [Reference Citation Analysis]
185 Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, Agaimy A, Amin MB, Argani P, Chen YB, Cheng L, Colecchia M, Compérat E, Werneck da Cunha I, Epstein JI, Gill AJ, Hes O, Hirsch MS, Jochum W, Kunju LP, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Nesi G, Osunkoya AO, Picken MM, Rao P, Reuter VE, de Oliveira Salles PG, Schultz L, Tickoo SK, Tomlins SA, Trpkov K, Amin MB. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. Am J Surg Pathol 2018;42:279-92. [PMID: 29309300 DOI: 10.1097/PAS.0000000000001000] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 19.8] [Reference Citation Analysis]
186 Uçar M, Soyupek S, Oksay T, Özorak A, Güzel A, Öztürk SA, Demir M, Koşar A. Renal kitle nedeniyle radikal nefrektomi yapılan hastaların tümör karakteristiklerinin değerlendirilmesi; 18 yıllık sonuçlarımız. SDÜ Tıp Fakültesi Dergisi 2019. [DOI: 10.17343/sdutfd.460209] [Reference Citation Analysis]
187 Tamura K, Horikawa M, Sato S, Miyake H, Setou M. Discovery of lipid biomarkers correlated with disease progression in clear cell renal cell carcinoma using desorption electrospray ionization imaging mass spectrometry. Oncotarget 2019;10:1688-703. [PMID: 30899441 DOI: 10.18632/oncotarget.26706] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
188 Raspollini MR, Cheng L, Montironi R, Lopez-beltran A. ♂♀ Clear Cell Tumors of the Kidney and the Gynecologic Tract. Gynecologic and Urologic Pathology 2019. [DOI: 10.1017/9781316756423.016] [Reference Citation Analysis]
189 Wang G, Yuan R, Tucker T, Gates AB, Bellamy CD, Hayes MM. Combined Papillary Renal Cell Carcinoma with Neuroendocrine Differentiation and Mucinous Tubular and Spindle Cell Carcinoma. Case Rep Pathol 2018;2018:8734823. [PMID: 30693127 DOI: 10.1155/2018/8734823] [Reference Citation Analysis]
190 He X, Zhang H, Zhang T, Han F, Song B. Predictive models composed by radiomic features extracted from multi-detector computed tomography images for predicting low- and high- grade clear cell renal cell carcinoma: A STARD-compliant article. Medicine (Baltimore) 2019;98:e13957. [PMID: 30633175 DOI: 10.1097/MD.0000000000013957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
191 Shen K, Vesey DA, Ellis RJ, Del Vecchio SJ, Cho Y, Teixeira-Pinto A, McGuckin MA, Johnson DW, Gobe GC. GRP78 expression in tumor and perinephric adipose tissue is not an optimal risk stratification marker for clear cell renal cell carcinoma. PLoS One 2019;14:e0210246. [PMID: 30653515 DOI: 10.1371/journal.pone.0210246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
192 Andreiana BC, Stepan AE, Mărgăritescu C, Al Khatib AM, Florescu MM, Ciurea RN, Simionescu CE. Histopathological Prognostic Factors in Clear Cell Renal Cell Carcinoma. Curr Health Sci J 2018;44:201-5. [PMID: 30647938 DOI: 10.12865/CHSJ.44.03.01] [Reference Citation Analysis]
193 Graham TM, Stevens TM, Gordetsky JB. Pathology of Renal Tumors. Diagnosis and Surgical Management of Renal Tumors 2019. [DOI: 10.1007/978-3-319-92309-3_2] [Reference Citation Analysis]
194 Bitar RD, Daw NC. Renal Cell Carcinoma in Children. Rare Kidney Tumors 2019. [DOI: 10.1007/978-3-319-96989-3_3] [Reference Citation Analysis]
195 Lim AR, Rathmell WK. Chromophobe Renal Cell Carcinoma. Rare Kidney Tumors 2019. [DOI: 10.1007/978-3-319-96989-3_4] [Reference Citation Analysis]
196 Hou W, Hoefflin R, Grüllich C, Hohenfellner M, Duensing S. Molecular Heterogeneity of Renal Cell Carcinoma. Urologic Oncology 2019. [DOI: 10.1007/978-3-319-42623-5_59] [Reference Citation Analysis]
197 Kondisetty G, Borkar PV, Kondisetty S, Thomas A. Retrospective review of experience with sarcomatoid renal cell carcinoma: Multimodality treatment remains an unmet goal. Urol Ann 2019;11:385-8. [PMID: 31649458 DOI: 10.4103/UA.UA_106_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
198 Offermann A, Kuempers C, Perner S. Histological (Sub)Classifications and Their Prognostic Impact in Renal Cell Carcinoma. Urologic Oncology 2019. [DOI: 10.1007/978-3-319-42623-5_60] [Reference Citation Analysis]
199 Delphine B, Damien A, Philippe B. Renal Cell Carcinoma with Sarcomatoid Features. Rare Kidney Tumors 2019. [DOI: 10.1007/978-3-319-96989-3_9] [Reference Citation Analysis]
200 Arora K, Psutka SP. Posttreatment Surveillance for Renal Cell Carcinoma. Diagnosis and Surgical Management of Renal Tumors 2019. [DOI: 10.1007/978-3-319-92309-3_16] [Reference Citation Analysis]
201 Caliò A, Segala D, Martignoni G. Clear Cell Renal Cell Carcinoma. Encyclopedia of Pathology 2019. [DOI: 10.1007/978-3-319-28845-1_4792-1] [Reference Citation Analysis]
202 Wu J, Xu WH, Wei Y, Qu YY, Zhang HL, Ye DW. An Integrated Score and Nomogram Combining Clinical and Immunohistochemistry Factors to Predict High ISUP Grade Clear Cell Renal Cell Carcinoma. Front Oncol 2018;8:634. [PMID: 30619768 DOI: 10.3389/fonc.2018.00634] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
203 Koparal MY, Polat F, Çetin S, Bulut EC, Sözen TS. Prognostic role of preoperative albumin to globulin ratio in predicting survival of clear cell renal cell carcinoma. Int Braz J Urol 2018;44:933-46. [PMID: 29757575 DOI: 10.1590/S1677-5538.IBJU.2018.0012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
204 Delahunt B, Egevad L, Yaxley J, Samaratunga H. The current status of renal cell carcinoma and prostate carcinoma grading. Int Braz J Urol 2018;44:1057-62. [PMID: 30516924 DOI: 10.1590/S1677-5538.IBJU.2018.06.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
205 Puttapirat P, Zhang H, Lian Y, Wang C, Zhang X, Yao L, Li C. OpenHI - An open source framework for annotating histopathological image. 2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) 2018. [DOI: 10.1109/bibm.2018.8621393] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
206 Yddoussalah O, Saouli A, Elouazzani H, Karmouni T, Khader K, Koutani A, Mahassini N, Andaloussi A. Carcinome rénal à cellules chromophobes : à propos de 16 cas et une revue de la littérature. African Journal of Urology 2018;24:291-295. [DOI: 10.1016/j.afju.2018.05.002] [Reference Citation Analysis]
207 Yao JX, Chen X, Xi W, Zhu YJ, Wang H, Hu XY, Guo JM. Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. J Cancer 2018;9:4099-107. [PMID: 30519309 DOI: 10.7150/jca.27408] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
208 Frascà GM, Brigante F, Volpe A, Cosmai L, Gallieni M, Porta C. Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. J Nephrol 2019;32:57-64. [PMID: 30328092 DOI: 10.1007/s40620-018-0542-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
209 Wang J, Liu L, Bai Q, Ou C, Xiong Y, Qu Y, Wang Z, Xia Y, Guo J, Xu J. Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. Oncoimmunology 2019;8:e1515611. [PMID: 30546957 DOI: 10.1080/2162402X.2018.1515611] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
210 Wi YC, Moon A, Jung MJ, Kim Y, Bang SS, Jang K, Paik SS, Shin SJ. Loss of Nuclear BAP1 Expression Is Associated with High WHO/ISUP Grade in Clear Cell Renal Cell Carcinoma. J Pathol Transl Med 2018;52:378-85. [PMID: 30269473 DOI: 10.4132/jptm.2018.09.21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
211 Warren AY, Harrison D. WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World J Urol 2018;36:1913-26. [PMID: 30123932 DOI: 10.1007/s00345-018-2447-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 15.4] [Reference Citation Analysis]
212 van Oostenbrugge TJ, Runneboom W, Bekers E, Heidkamp J, Langenhuijsen JF, Veltien A, Maat A, Mulders PFA, Hulsbergen-van de Kaa CA, Fütterer JJ. MRI as a tool to assess surgical margins and pseudocapsule features directly following partial nephrectomy for small renal masses. Eur Radiol 2019;29:509-16. [PMID: 30043161 DOI: 10.1007/s00330-018-5630-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
213 Kammerer-jacquet S, Thierry S, Rioux-leclercq N. Cancers du rein : évolution de la classification anatomopathologique. Oncol 2018;20:193-198. [DOI: 10.3166/onco-2019-0025] [Reference Citation Analysis]
214 Zhang L, Wu B, Zha Z, Zhao H, Feng Y. The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis. Cancer Manag Res 2018;10:1687-703. [PMID: 29970967 DOI: 10.2147/CMAR.S166710] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
215 Park JH, Lee C, Chang MS, Kim K, Choi S, Lee H, Lee HS, Moon KC. Molecular Characterization and Putative Pathogenic Pathways of Tuberous Sclerosis Complex-Associated Renal Cell Carcinoma. Transl Oncol 2018;11:962-70. [PMID: 29925043 DOI: 10.1016/j.tranon.2018.05.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
216 Cajaiba MM, Dyer LM, Geller JI, Jennings LJ, George D, Kirschmann D, Rohan SM, Cost NG, Khanna G, Mullen EA, Dome JS, Fernandez CV, Perlman EJ. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer 2018;124:3381-9. [PMID: 29905933 DOI: 10.1002/cncr.31578] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 9.6] [Reference Citation Analysis]
217 Yap NY, Ong TA, Morais C, Pailoor J, Gobe GC, Rajandram R. Establishment of epithelial and fibroblast cell lines from primary renal cancer nephrectomies.. [DOI: 10.1101/337055] [Reference Citation Analysis]
218 Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol 2019;37:115-23. [PMID: 29858701 DOI: 10.1007/s00345-018-2355-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
219 Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol 2018;36:1943-52. [PMID: 29713755 DOI: 10.1007/s00345-018-2309-4] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 16.2] [Reference Citation Analysis]
220 Bier G, Bier S, Bongers MN, Othman A, Ernemann U, Hempel JM. Value of computed tomography texture analysis for prediction of perioperative complications during laparoscopic partial nephrectomy in patients with renal cell carcinoma. PLoS One 2018;13:e0195270. [PMID: 29668695 DOI: 10.1371/journal.pone.0195270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
221 Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, O'Brien T, Lopez JI, Watkins TBK, Nicol D, Stares M, Challacombe B, Hazell S, Chandra A, Mitchell TJ, Au L, Eichler-Jonsson C, Jabbar F, Soultati A, Chowdhury S, Rudman S, Lynch J, Fernando A, Stamp G, Nye E, Stewart A, Xing W, Smith JC, Escudero M, Huffman A, Matthews N, Elgar G, Phillimore B, Costa M, Begum S, Ward S, Salm M, Boeing S, Fisher R, Spain L, Navas C, Grönroos E, Hobor S, Sharma S, Aurangzeb I, Lall S, Polson A, Varia M, Horsfield C, Fotiadis N, Pickering L, Schwarz RF, Silva B, Herrero J, Luscombe NM, Jamal-Hanjani M, Rosenthal R, Birkbak NJ, Wilson GA, Pipek O, Ribli D, Krzystanek M, Csabai I, Szallasi Z, Gore M, McGranahan N, Van Loo P, Campbell P, Larkin J, Swanton C; TRACERx Renal Consortium. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell 2018;173:595-610.e11. [PMID: 29656894 DOI: 10.1016/j.cell.2018.03.043] [Cited by in Crossref: 322] [Cited by in F6Publishing: 256] [Article Influence: 64.4] [Reference Citation Analysis]
222 Xiong Y, Liu L, Xia Y, Wang J, Xi W, Bai Q, Qu Y, Long Q, Xu J, Guo J. High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. Oncotarget 2016;7:63661-8. [PMID: 27564117 DOI: 10.18632/oncotarget.11606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
223 Cocco E, Leo M, Canzonetta C, Di Vito S, Mai A, Rotili D, Di Napoli A, Vecchione A, De Nunzio C, Filetici P, Stoppacciaro A. KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2. Clin Epigenetics 2018;10:44. [PMID: 29632619 DOI: 10.1186/s13148-018-0473-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
224 Tailor PD, Kodeboyina SK, Bai S, Patel N, Sharma S, Ratnani A, Copland JA, She JX, Sharma A. Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types. Oncotarget 2018;9:17876-88. [PMID: 29707153 DOI: 10.18632/oncotarget.24947] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
225 Nini A, Larcher A, Cianflone F, Trevisani F, Terrone C, Volpe A, Regis F, Briganti A, Salonia A, Montorsi F, Bertini R, Capitanio U. The Effect of Anatomical Location of Lymph Node Metastases on Cancer Specific Survival in Patients with Clear Cell Renal Cell Carcinoma. Front Surg 2018;5:26. [PMID: 29740587 DOI: 10.3389/fsurg.2018.00026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
226 Gaspar BL, Gupta K, Singh AP, Salunke P. A 39-Year-Old Gentleman with Headache, Visual Blurring and a Renal Mass. Brain Pathol 2018;28:301-2. [PMID: 29516661 DOI: 10.1111/bpa.12589] [Reference Citation Analysis]
227 Xiong Y, Liu L, Wang J, Xi W, Xia Y, Bai Q, Qu Y, Long Q, Xu J, Guo J. Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma. Oncotarget 2017;8:25650-9. [PMID: 27783999 DOI: 10.18632/oncotarget.12827] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
228 Xu Z, Liu Y, Yang Y, Wang J, Zhang G, Liu Z, Fu H, Wang Z, Liu H, Xu J. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget 2017;8:7548-58. [PMID: 27911274 DOI: 10.18632/oncotarget.13692] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
229 Buti S, Puligandla M, Bersanelli M, DiPaola RS, Manola J, Taguchi S, Haas NB. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. Ann Oncol 2017;28:2747-53. [PMID: 28945839 DOI: 10.1093/annonc/mdx492] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
230 Kim H, Inomoto C, Uchida T, Furuya H, Komiyama T, Kajiwara H, Kobayashi H, Nakamura N, Miyajima A. Verification of the International Society of Urological Pathology recommendations in Japanese patients with clear cell renal cell carcinoma. Int J Oncol. 2018;52:1139-1148. [PMID: 29532874 DOI: 10.3892/ijo.2018.4294] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
231 Qu Y, Liu L, Wang J, Xi W, Xia Y, Bai Q, Xiong Y, Long Q, Xu J, Guo J. Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma. Oncotarget 2016;7:84775-84. [PMID: 27713173 DOI: 10.18632/oncotarget.12476] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
232 Razafinjatovo CF, Stiehl D, Deininger E, Rechsteiner M, Moch H, Schraml P. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma. Oncotarget 2017;8:10199-212. [PMID: 28052007 DOI: 10.18632/oncotarget.14372] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
233 Doehn C, Grünwald V, Steiner T, Follmann M, Rexer H, Krege S. The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma. Dtsch Arztebl Int 2016;113:590-6. [PMID: 27658472 DOI: 10.3238/arztebl.2016.0590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
234 Wang J, Liu Y, Yang Y, Xu Z, Zhang G, Liu Z, Fu H, Wang Z, Liu H, Xu J. High expression of galectin-7 associates with poor overall survival in patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget 2016;7:41986-95. [PMID: 27259255 DOI: 10.18632/oncotarget.9749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
235 Ha US, Lee KW, Jung JH, Byun SS, Kwak C, Chung J, Hwang EC, Kim YJ, Kwon TG, Kang SH, Hong SH. Renal capsular invasion is a prognostic biomarker in localized clear cell renal cell carcinoma. Sci Rep 2018;8:202. [PMID: 29317731 DOI: 10.1038/s41598-017-18466-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
236 Nierenzellkarzinom. Urologische Tumoren 2018. [DOI: 10.1016/b978-3-437-21161-4.00002-x] [Reference Citation Analysis]
237 McClain A, Sakowski L, Conti M, Zhang H, Li QK. Intranuclear Inclusions in Conventional Clear Cell Renal Cell Carcinoma (ccRCC): Diagnosis and Differential Diagnosis. Arch Urol Res 2018;2:5-7. [PMID: 31565700 DOI: 10.17352/aur.000003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
238 Delahunt B, Egevad L, Srigley JR, Samaratunga H. Fuhrman grading is inappropriate for papillary renal cell carcinoma. World J Urol 2018;36:1335-6. [PMID: 29256019 DOI: 10.1007/s00345-017-2153-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
239 Herman D, Mantle P. Immunohistochemical Analysis of Rat Renal Tumours Caused by Ochratoxin A. Toxins (Basel) 2017;9:E384. [PMID: 29182526 DOI: 10.3390/toxins9120384] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
240 Zhang X, Ji J, Zhang G, Fang C, Jiang F, Ma S, Hou J. Expression and significance of B7-H3 and Tie-2 in the tumor vasculature of clear cell renal carcinoma. Onco Targets Ther 2017;10:5417-24. [PMID: 29180874 DOI: 10.2147/OTT.S147041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
241 Williamson SR. The Many Faces of Renal Cell Carcinoma in End-Stage Renal Disease. AJSP: Reviews and Reports 2017;22:290-296. [DOI: 10.1097/pcr.0000000000000216] [Reference Citation Analysis]
242 Banach BS, Paner GP. Chromophobe Renal Cell Carcinoma With High-Grade Features. AJSP: Reviews and Reports 2017;22:282-285. [DOI: 10.1097/pcr.0000000000000217] [Reference Citation Analysis]
243 Zheng I, Alameddine M, Tan Y, Moghadamyeghaneh Z, Jue JS, Yusufali A, Farag A, Ciancio G. Collecting Duct Carcinoma of the Native Kidney in a Renal Transplant Recipient. Case Rep Transplant 2017;2017:4527104. [PMID: 29062581 DOI: 10.1155/2017/4527104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
244 Miles J, Applebee CJ, Leboucher P, Lopez-Fernandez S, Lee DJ, Guarch R, Ward S, Parker PJ, López JI, Larijani B. Time resolved amplified FRET identifies protein kinase B activation state as a marker for poor prognosis in clear cell renal cell carcinoma. BBA Clin 2017;8:97-102. [PMID: 29296589 DOI: 10.1016/j.bbacli.2017.10.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
245 Go H, Kang MJ, Kim PJ, Lee JL, Park JY, Park JM, Ro JY, Cho YM. Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma. Pathol Oncol Res 2019;25:51-8. [PMID: 28963640 DOI: 10.1007/s12253-017-0323-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
246 Xie Y, Ma X, Li H, Gao Y, Gu L, Chen L, Zhang X. Prognostic Value of Clinical and Pathological Features in Chinese Patients with Chromophobe Renal Cell Carcinoma: A 10-Year Single-Center Study. J Cancer 2017;8:3474-9. [PMID: 29151931 DOI: 10.7150/jca.19953] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
247 Flippot R, Mouawad R, Spano JP, Rouprêt M, Compérat E, Bitker MO, Parra J, Vaessen C, Allanic F, Manach Q, Tannir NM, Khayat D, Su X, Malouf GG. Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. Sci Rep 2017;7:8540. [PMID: 28819235 DOI: 10.1038/s41598-017-08363-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
248 Park JH, Jung M, Moon KC. The prognostic significance of nuclear expression of PHF2 and C/EBPα in clear cell renal cell carcinoma with consideration of adipogenic metabolic evolution. Oncotarget 2018;9:142-51. [PMID: 29416602 DOI: 10.18632/oncotarget.19949] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
249 Zhang Y, Udayakumar D, Cai L, Hu Z, Kapur P, Kho EY, Pavía-Jiménez A, Fulkerson M, de Leon AD, Yuan Q, Dimitrov IE, Yokoo T, Ye J, Mitsche MA, Kim H, McDonald JG, Xi Y, Madhuranthakam AJ, Dwivedi DK, Lenkinski RE, Cadeddu JA, Margulis V, Brugarolas J, DeBerardinis RJ, Pedrosa I. Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI. JCI Insight 2017;2:94278. [PMID: 28768909 DOI: 10.1172/jci.insight.94278] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
250 Mehdi MZ, Nagi AH, Naseem N. MCM - 2 and Ki - 67 as proliferation markers in renal cell carcinoma: A quantitative and semi - quantitative analysis. Int Braz J Urol 2016;42:1121-8. [PMID: 27532114 DOI: 10.1590/S1677-5538.IBJU.2015.0388] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
251 Smith SC, Trpkov K, Chen YB, Mehra R, Sirohi D, Ohe C, Cani AK, Hovelson DH, Omata K, McHugh JB, Jochum W, Colecchia M, Amin M, Divatia MK, Hes O, Menon S, Werneck da Cunha I, Tripodi S, Brimo F, Gill AJ, Osunkoya AO, Magi-Galluzzi C, Sibony M, Williamson SR, Nesi G, Picken MM, Maclean F, Agaimy A, Cheng L, Epstein JI, Reuter VE, Tickoo SK, Tomlins SA, Amin MB. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma. Am J Surg Pathol 2016;40:1457-72. [PMID: 27635946 DOI: 10.1097/PAS.0000000000000719] [Cited by in Crossref: 90] [Cited by in F6Publishing: 94] [Article Influence: 15.0] [Reference Citation Analysis]
252 Tang L, Li X, Gao Y, Chen L, Gu L, Chen J, Lyu X, Zhang Y, Zhang X. Phosphatase and tensin homolog (PTEN) expression on oncologic outcome in renal cell carcinoma: A systematic review and meta-analysis. PLoS One 2017;12:e0179437. [PMID: 28672019 DOI: 10.1371/journal.pone.0179437] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
253 Du Y, Wang Q, Zhang X, Wang X, Qin C, Sheng Z, Yin H, Jiang C, Li J, Xu T. Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2017;36:66. [PMID: 28494778 DOI: 10.1186/s13046-017-0525-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 7.7] [Reference Citation Analysis]
254 Meng L, Xu L, Yang Y, Zhou L, Chang Y, Shi T, Tan C, An H, Zhu Y, Xu J. High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma. Oncotarget 2017;8:61036-47. [PMID: 28977844 DOI: 10.18632/oncotarget.17717] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
255 Xu M. Plum pudding random medium model of biological tissue toward remote microscopy from spectroscopic light scattering. Biomed Opt Express 2017;8:2879-95. [PMID: 28663913 DOI: 10.1364/BOE.8.002879] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
256 Park SH, Oh YT, Jung DC, Cho NH, Choi YD, Park SY. Abdominal seeding of renal cell carcinoma: radiologic, pathologic, and prognostic features. Abdom Radiol (NY) 2017;42:1510-6. [PMID: 28084547 DOI: 10.1007/s00261-016-1029-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
257 Chen C, Kang Q, Wei Q, Xu B, Ye H, Wang T, Lu Y, Lu J. Correlation between CT perfusion parameters and Fuhrman grade in pTlb renal cell carcinoma. Abdom Radiol (NY) 2017;42:1464-71. [PMID: 27999886 DOI: 10.1007/s00261-016-1009-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
258 Parada Villavicencio C, Mc Carthy RJ, Miller FH. Can diffusion-weighted magnetic resonance imaging of clear cell renal carcinoma predict low from high nuclear grade tumors. Abdom Radiol (NY) 2017;42:1241-9. [PMID: 27904923 DOI: 10.1007/s00261-016-0981-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
259 Xiong Y, Liu L, Xia Y, Wang J, Xi W, Bai Q, Qu Y, Xu J, Guo J. Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma. BMC Cancer 2017;17:117. [PMID: 28178948 DOI: 10.1186/s12885-017-3106-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
260 Doehn C. Systemische Therapie des metastasierten Nierenzellkarzinoms. Info Onkol 2017;20:31-40. [DOI: 10.1007/s15004-017-5557-3] [Reference Citation Analysis]
261 Moch H. [WHO classification 2016 and first S3 guidelines on renal cell cancer: What is important for the practice?]. Pathologe 2016;37:127-33. [PMID: 26942728 DOI: 10.1007/s00292-016-0144-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
262 Xia Y, Liu L, Xiong Y, Bai Q, Wang J, Xi W, Qu Y, Xu J, Guo J. Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. BMC Cancer 2017;17:70. [PMID: 28114889 DOI: 10.1186/s12885-017-3065-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
263 Hou W, Hoefflin R, Grüllich C, Hohenfellner M, Duensing S. Molecular Heterogeneity of Renal Cell Carcinoma. Urologic Oncology 2017. [DOI: 10.1007/978-3-319-42603-7_59-1] [Reference Citation Analysis]
264 O’rourke DM, Allen DC. Kidney, Renal Pelvis, and Ureter. Histopathology Specimens 2017. [DOI: 10.1007/978-3-319-57360-1_29] [Reference Citation Analysis]
265 Offermann A, Kuempers C, Perner S. Histological (Sub)Classifications and Their Prognostic Impact in Renal Cell Carcinoma. Urologic Oncology 2017. [DOI: 10.1007/978-3-319-42603-7_60-1] [Reference Citation Analysis]
266 Chang S, Loda M. Pathology and Molecular Pathology of Renal Cancer. Pathology and Epidemiology of Cancer 2017. [DOI: 10.1007/978-3-319-35153-7_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
267 Kuthi L, Jenei A, Hajdu A, Németh I, Varga Z, Bajory Z, Pajor L, Iványi B. Prognostic Factors for Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification: a Study Involving 928 Patients. Pathol Oncol Res 2017;23:689-98. [PMID: 28032311 DOI: 10.1007/s12253-016-0179-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
268 Fu Q, Chang Y, Zhou L, An H, Zhu Y, Xu L, Zhang W, Xu J. Positive intratumoral chemokine (C-C motif) receptor 8 expression predicts high recurrence risk of post-operation clear-cell renal cell carcinoma patients. Oncotarget 2016;7:8413-21. [PMID: 26716905 DOI: 10.18632/oncotarget.6761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
269 Salmond JM. Pathology of tumours of the kidney and urinary tract. Surgery (Oxford) 2016;34:487-492. [DOI: 10.1016/j.mpsur.2016.07.005] [Reference Citation Analysis]
270 Porta C, Chiellino S. ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics. Ann Transl Med 2016;4:S14. [PMID: 27867982 DOI: 10.21037/atm.2016.10.45] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
271 Maurice MJ, Zhu H, Kim S, Abouassaly R. Survival after partial and radical nephrectomy for high-risk disease: A propensity-matched comparison. Can Urol Assoc J 2016;10:E282-9. [PMID: 27695581 DOI: 10.5489/cuaj.3707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
272 Xia Y, Liu L, Bai Q, Wang J, Xi W, Qu Y, Xiong Y, Long Q, Xu J, Guo J. Dectin-1 predicts adverse postoperative prognosis of patients with clear cell renal cell carcinoma. Sci Rep 2016;6:32657. [PMID: 27600310 DOI: 10.1038/srep32657] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
273 Khor L, Dhakal HP, Jia X, Reynolds JP, Mckenney JK, Rini BI, Magi-galluzzi C, Przybycin CG. Tumor Necrosis Adds Prognostically Significant Information to Grade in Clear Cell Renal Cell Carcinoma: A Study of 842 Consecutive Cases From a Single Institution. American Journal of Surgical Pathology 2016;40:1224-31. [DOI: 10.1097/pas.0000000000000690] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
274 Xia Y, Liu L, Xiong Y, Bai Q, Wang J, Xi W, Qu Y, Xu J, Guo J. Podoplanin associates with adverse postoperative prognosis of patients with clear cell renal cell carcinoma. Cancer Sci 2016;107:1243-9. [PMID: 27389969 DOI: 10.1111/cas.13007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
275 Cros J, Sbidian E, Posseme K, Letierce A, Guettier C, Benoît G, Ferlicot S. Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma. Virchows Arch 2016;469:331-7. [PMID: 27311769 DOI: 10.1007/s00428-016-1973-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
276 Parker WP, Cheville JC, Frank I, Zaid HB, Lohse CM, Boorjian SA, Leibovich BC, Thompson RH. Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients. Eur Urol 2017;71:665-73. [PMID: 27287995 DOI: 10.1016/j.eururo.2016.05.034] [Cited by in Crossref: 52] [Cited by in F6Publishing: 60] [Article Influence: 7.4] [Reference Citation Analysis]
277 Kara O, Maurice MJ, Zargar H, Malkoc E, Akca O, Andrade HS, Ramirez D, Caputo PA, Nelson RJ, Rini B, Kaouk JH. Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma. Int Urol Nephrol 2016;48:1253-60. [PMID: 27215555 DOI: 10.1007/s11255-016-1314-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
278 Lopez JI. Case Report: Multifocal biphasic squamoid alveolar renal cell carcinoma. F1000Res 2016;5:607. [PMID: 27158455 DOI: 10.12688/f1000research.8451.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
279 Lopez JI. Case Report: Multifocal biphasic squamoid alveolar renal cell carcinoma. F1000Res 2016;5:607. [PMID: 27158455 DOI: 10.12688/f1000research.8451.2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
280 Nguyen DP, Vertosick EA, Corradi RB, Vilaseca A, Benfante NE, Touijer KA, Sjoberg DD, Russo P. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urol Oncol 2016;34:259.e1-8. [PMID: 26947350 DOI: 10.1016/j.urolonc.2016.01.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
281 Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, Srigley JR. Gleason and Fuhrman no longer make the grade. Histopathology 2016;68:475-81. [PMID: 26266664 DOI: 10.1111/his.12803] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
282 Kristiansen G, Delahunt B, Srigley JR, Lüders C, Lunkenheimer JM, Gevensleben H, Thiesler T, Montironi R, Egevad L. [Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)]. Pathologe 2015;36:310-6. [PMID: 25398389 DOI: 10.1007/s00292-014-2030-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
283 Othmane Y, Mounir L, Tarik K, Khalid E, Abdellatif K, Ahmed IA. [Chromophobe renal cell carcinoma: about four cases and review of the literature]. Pan Afr Med J 2015;22:123. [PMID: 26889304 DOI: 10.11604/pamj.2015.22.123.6741] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
284 Moch H. [Kidney tumours]. Pathologe 2016;37:125-6. [PMID: 26886133 DOI: 10.1007/s00292-016-0146-z] [Reference Citation Analysis]
285 Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A 2016;113:2170-5. [PMID: 26864202 DOI: 10.1073/pnas.1525735113] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 12.1] [Reference Citation Analysis]
286 Derweesh IH, Raheem OA, Shabaik A. Conventional Forms of Renal Neoplasia. The Kidney 2016. [DOI: 10.1007/978-1-4939-3286-3_5] [Reference Citation Analysis]
287 Chromophobe Renal Cell Carcinoma. Diagnostic Pathology: Genitourinary 2016. [DOI: 10.1016/b978-0-323-37714-0.50024-9] [Reference Citation Analysis]
288 Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F, He Z, Sheng X, Bi F, Cao D, Chen Y, Huang Y, Liang H, Liang J, Liu J, Liu W, Pan Y, Shu Y, Song X, Wang W, Wang X, Wu X, Xie X, Yao X, Yu S, Zhang Y, Zhou A; written; CSCO Renal Cell Carcinoma Committee. Chinese guidelines on the management of renal cell carcinoma (2015 edition). Ann Transl Med. 2015;3:279. [PMID: 26697439 DOI: 10.3978/j.issn.2305-5839.2015.11.21] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
289 Rausch S, Scharpf M, Moch H, Stenzl A, Bedke J. [Leiomyomatous renal cell carcinoma : Controversy around a new entity]. Urologe A 2016;55:376-80. [PMID: 26556266 DOI: 10.1007/s00120-015-3975-0] [Reference Citation Analysis]
290 Fu Q, Chang Y, An H, Fu H, Zhu Y, Xu L, Zhang W, Xu J. Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis. Br J Cancer 2015;113:1581-9. [PMID: 26554658 DOI: 10.1038/bjc.2015.379] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
291 Park I, Cho YM, Lee JL, Ahn JH, Lee DH. Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Tumour Biol 2016;37:4919-27. [PMID: 26526582 DOI: 10.1007/s13277-015-4339-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
292 Leite KR, Reis ST, Junior JP, Zerati M, Gomes Dde O, Camara-Lopes LH, Srougi M. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn Pathol 2015;10:189. [PMID: 26470780 DOI: 10.1186/s13000-015-0414-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
293 Shin SJ, Jeon YK, Cho YM, Lee JL, Chung DH, Park JY, Go H. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Oncologist 2015;20:1253-60. [PMID: 26424759 DOI: 10.1634/theoncologist.2015-0151] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
294 Ledezma RA, Negron E, Paner GP, Rjepaj C, Lascano D, Haseebuddin M, Dangle P, Shalhav AL, Crist H, Raman JD, Joel DeCastro G, Harik L, Paroder M, Uzzo RG, Kutikov A, Eggener SE. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol 2016;34:687-93. [PMID: 26407582 DOI: 10.1007/s00345-015-1692-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
295 Ambrosio MR, Rocca BJ, Barone A, Onorati M, Mundo L, Crivelli F, Di Nuovo F, De Falco G, del Vecchio MT, Tripodi SA, Tosi P. Expression of Translationally Controlled Tumor Protein in Human Kidney and in Renal Cell Carcinoma. Biomed Res Int 2015;2015:730390. [PMID: 26425551 DOI: 10.1155/2015/730390] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
296 Miolo G, Ash A, Buonadonna A, Lo Re G, Torrisi E, Cervo S, Santeufemia DA, Tuzi A, Canzonieri V. Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications. Cancer Biol Ther 2014;15:1439-43. [PMID: 25482943 DOI: 10.4161/15384047.2014.956642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
297 Nguyen DP, Vilaseca A, Vertosick EA, Corradi RB, Touijer KA, Benfante NE, Sjoberg DD, Russo P. Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically. World J Urol 2016;34:539-44. [PMID: 26215750 DOI: 10.1007/s00345-015-1644-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
298 Zhang BY, Cheville JC, Thompson RH, Lohse CM, Boorjian SA, Leibovich BC, Costello BA. Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma. Eur Urol 2015;68:5-7. [PMID: 25638439 DOI: 10.1016/j.eururo.2015.01.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
299 Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol 2015;28:1225-35. [PMID: 26111976 DOI: 10.1038/modpathol.2015.68] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
300 Busch J, Ralla B, Jung M, Wotschofsky Z, Trujillo-Arribas E, Schwabe P, Kilic E, Fendler A, Jung K. Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. J Exp Clin Cancer Res 2015;34:61. [PMID: 26071182 DOI: 10.1186/s13046-015-0180-3] [Cited by in Crossref: 68] [Cited by in F6Publishing: 77] [Article Influence: 8.5] [Reference Citation Analysis]
301 Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol 2015;33:427.e17-23. [PMID: 26004164 DOI: 10.1016/j.urolonc.2015.04.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
302 Kadota K, Nitadori J, Woo KM, Sima CS, Finley DJ, Rusch VW, Adusumilli PS, Travis WD. Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes. J Thorac Oncol 2014;9:1126-39. [PMID: 24942260 DOI: 10.1097/JTO.0000000000000253] [Cited by in Crossref: 77] [Cited by in F6Publishing: 86] [Article Influence: 9.6] [Reference Citation Analysis]
303 Wala SJ, Karamchandani JR, Saleeb R, Evans A, Ding Q, Ibrahim R, Jewett M, Pasic M, Finelli A, Pace K, Lianidou E, Yousef GM. An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways. Mol Oncol 2015;9:1667-77. [PMID: 26051997 DOI: 10.1016/j.molonc.2015.04.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
304 Lopez-beltran A, Delahunt B, Srigley JR, Egevad L, Montironi R. The International Society of Urological Pathology Consensus Conference regarding the classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Revista Española de Patología 2015;48:90-96. [DOI: 10.1016/j.patol.2014.09.008] [Reference Citation Analysis]
305 Cornejo KM, Lu M, Yang P, Wu S, Cai C, Zhong WD, Olumi A, Young RH, Wu CL. Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma. Hum Pathol 2015;46:820-6. [PMID: 25827535 DOI: 10.1016/j.humpath.2015.02.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
306 Chen X, Li S, Xu Z, Wang K, Fu D, Liu Q, Wang X, Wu B. Clinical and oncological outcomes in Chinese patients with renal cell carcinoma and venous tumor thrombus extension: single-center experience. World J Surg Oncol 2015;13:14. [PMID: 25650039 DOI: 10.1186/s12957-015-0448-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
307 Alshenawy HA. Immunohistochemical panel for differentiating renal cell carcinoma with clear and papillary features. J Microsc Ultrastruct 2015;3:68-74. [PMID: 30023184 DOI: 10.1016/j.jmau.2015.01.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
308 Przybycin CG, Wu A, Kunju LP. Surgical Pathology Reporting of Renal Cell Carcinomas. Genitourinary Pathology 2015. [DOI: 10.1007/978-1-4939-2044-0_25] [Reference Citation Analysis]
309 Sukov WR, Cheville JC. Classification of Adult Renal Tumors and Grading of Renal Cell Carcinoma. Genitourinary Pathology 2015. [DOI: 10.1007/978-1-4939-2044-0_23] [Reference Citation Analysis]
310 Lopez-beltran A, Menendez CL, Montironi R, Cheng L. Renal Tumors and Tumor-Like Conditions. Rare Tumors and Tumor-like Conditions in Urological Pathology 2015. [DOI: 10.1007/978-3-319-10253-5_1] [Reference Citation Analysis]
311 Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ 2014;349:g4797. [PMID: 25385470 DOI: 10.1136/bmj.g4797] [Cited by in Crossref: 312] [Cited by in F6Publishing: 352] [Article Influence: 34.7] [Reference Citation Analysis]
312 Zhang M, Wah C, Epstein JI. Metastatic Renal Cell Carcinoma to the Urinary Bladder: A Report of 11 Cases. American Journal of Surgical Pathology 2014;38:1516-21. [DOI: 10.1097/pas.0000000000000257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
313 Fu Q, Liu Z, Pan D, Zhang W, Xu L, Zhu Y, Liu H, Xu J. Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. Cancer Sci 2014;105:1427-34. [PMID: 25155155 DOI: 10.1111/cas.12507] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
314 Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, Stanton ML, Hodi FS, McDermott DF, Atkins MB, Freeman GJ, Hirsch MS, Signoretti S. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 2014;25:2178-84. [PMID: 25193987 DOI: 10.1093/annonc/mdu445] [Cited by in Crossref: 201] [Cited by in F6Publishing: 215] [Article Influence: 22.3] [Reference Citation Analysis]
315 Steffens S, Roos FC, Janssen M, Becker F, Steinestel J, Abbas M, Steinestel K, Wegener G, Siemer S, Thüroff JW, Hofmann R, Stöckle M, Schrader M, Hartmann A, Junker K, Kuczyk MA, Schrader AJ; German Renal Cell Cancer Network. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size. Virchows Arch 2014;465:439-44. [PMID: 25178561 DOI: 10.1007/s00428-014-1648-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
316 Yang P, Cornejo KM, Sadow PM, Cheng L, Wang M, Xiao Y, Jiang Z, Oliva E, Jozwiak S, Nussbaum RL, Feldman AS, Paul E, Thiele EA, Yu JJ, Henske EP, Kwiatkowski DJ, Young RH, Wu CL. Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol 2014;38:895-909. [PMID: 24832166 DOI: 10.1097/PAS.0000000000000237] [Cited by in Crossref: 161] [Cited by in F6Publishing: 166] [Article Influence: 17.9] [Reference Citation Analysis]
317 Yeh FC, Parwani AV, Pantanowitz L, Ho C. Automated grading of renal cell carcinoma using whole slide imaging. J Pathol Inform 2014;5:23. [PMID: 25191622 DOI: 10.4103/2153-3539.137726] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
318 Samaratunga H, Gianduzzo T, Delahunt B. The ISUP system of staging, grading and classification of renal cell neoplasia. J Kidney Cancer VHL 2014;1:26-39. [PMID: 28326247 DOI: 10.15586/jkcvhl.2014.11] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
319 Warrick JI, Tsodikov A, Kunju LP, Chinnaiyan AM, Palapattu GS, Morgan TM, Alva A, Tomlins S, Wu A, Montgomery JS, Hafez KS, Wolf JS Jr, Weizer AZ, Mehra R. Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. Hum Pathol 2014;45:1139-46. [PMID: 24767860 DOI: 10.1016/j.humpath.2014.02.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
320 Moch H, Srigley J, Delahunt B, Montironi R, Egevad L, Tan PH. Biomarkers in renal cancer. Virchows Arch 2014;464:359-65. [PMID: 24487793 DOI: 10.1007/s00428-014-1546-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
321 Rioux-leclercq N. Prise en charge macroscopique d'une tumeur du rein – Classifications OMS et TNM – Facteurs pronostiques – Place de la biopsie et de l'examen extemporané. Pathologie Tumorale Rénale 2014. [DOI: 10.1016/b978-2-294-73736-7.00003-3] [Reference Citation Analysis]